Clinical Notes

Clinical Case Study

Urinary Urgency in an Elderly Patient

  -   Patient Profile

An elderly female patient presented with persistent complaints of urinary urgency. During the initial consultation, it was discussed that age-related changes could contribute to symptoms such as urinary leakage; however, the patient's presentation suggested a more complex underlying condition. Based on the symptomatology and the lack of initial improvement, further evaluation was deemed necessary.

  -   Clinical Considerations

Urinary urgency in elderly patients may arise from a variety of causes. In this case, possible differential diagnoses included overactive bladder (OAB), urinary tract infection (UTI), atrophic vaginitis or urethritis, detrusor hyperactivity with impaired contractility (DHIC), and potential structural issues such as bladder outlet obstruction or pelvic organ prolapse.

To manage symptoms, an initial prescription of bethanechol was issued. Bethanechol, a cholinergic agonist, is typically indicated for patients with urinary retention due to detrusor muscle underactivity. The medication can be effective in cases where the bladder cannot contract adequately, such as in postoperative urinary retention or neurogenic bladder conditions. Its mechanism of action involves stimulating bladder muscle contraction, which is particularly useful for patients experiencing bladder atony or areflexia.

  -   Further Diagnostic and Treatment Approaches

Given that bethanechol is generally reserved for cases involving inadequate bladder contraction rather than symptoms of urgency, additional diagnostic measures were recommended to confirm the underlying cause. Potential therapeutic interventions, considering other differential diagnoses, included:

• Antimuscarinics: Medications such as oxybutynin or tolterodine could be considered, as they reduce bladder muscle spasms, alleviating urgency commonly associated with OAB.
• Beta-3 Agonists: Mirabegron could serve as an alternative, especially if antimuscarinics were contraindicated due to potential side effects such as dry mouth and constipation.
• Topical Estrogen Therapy: For patients experiencing atrophic vaginitis, local estrogen application could be beneficial, addressing estrogen deficiency that may contribute to urinary symptoms.
• Alpha-blockers: Although more frequently prescribed for male patients, alpha-blockers might be useful in cases where bladder outlet obstruction or pelvic organ prolapse was suspected, thereby easing urinary symptoms.
• Behavioral Therapies and Lifestyle Modifications: Recommendations for pelvic floor exercises, bladder training, and adjustments in fluid and caffeine intake were advised to support pharmacological treatment.

Written on October 16, 2024

Adult Nocturnal Enuresis

  -   Patient Profile

An elderly male patient presented with complaints of nocturnal enuresis, describing a pattern reminiscent of childhood bedwetting. He reported experiencing frequent episodes of involuntary urination during the night, which had recently increased in frequency.

  -   Clinical Considerations

In adults, nocturnal enuresis may arise from several potential causes, including overactive bladder, sleep disorders, excessive nighttime urine production (nocturnal polyuria), or bladder outlet obstruction. Given the patient's age, comprehensive evaluation was necessary to determine the underlying cause and guide appropriate management.

  -   Treatment Options and Rationale

After a thorough assessment of the patient's symptoms and health status, several pharmacological options were considered:

• Desmopressin: As a synthetic analog of vasopressin, desmopressin was deemed suitable for cases of nocturnal polyuria by reducing nighttime urine production. It is particularly effective in patients with high urine output during the night, provided there are no contraindications, such as hyponatremia or severe cardiovascular issues.
• Antimuscarinics: Medications such as oxybutynin, tolterodine, or solifenacin were considered to address symptoms related to overactive bladder. These agents work by reducing involuntary bladder contractions, which could help alleviate the frequency of nighttime urination.
• Tricyclic Antidepressants (Imipramine): Although not a first-line treatment, imipramine may be beneficial due to its anticholinergic effects, which decrease bladder activity. However, the potential side effects, especially in elderly patients, necessitate careful monitoring.
• Alpha-blockers: For cases where nocturnal enuresis might be related to bladder outlet obstruction, particularly in male patients, alpha-blockers such as tamsulosin or alfuzosin can help relax the muscles of the bladder neck and prostate, thereby improving urine flow and reducing nighttime symptoms.

  -   Behavioral and Lifestyle Modifications

In addition to pharmacological interventions, the patient was advised to adopt lifestyle modifications, such as reducing fluid intake in the evening, avoiding caffeinated or alcoholic beverages, and establishing a regular nighttime bathroom routine to mitigate the frequency of nocturnal urination.

Written in October 16, 2024

Management of Liver Failure in an Alcoholic Patient with Indigestion Symptoms

  -   Case Summary

A patient with a history of chronic alcoholism presented with symptoms of bloating, indigestion, and suspected liver failure. The patient experienced persistent gastrointestinal discomfort, leading to the administration of an injectable anti-nausea medication to alleviate these symptoms. Due to the patient's underlying liver dysfunction, careful consideration was required in selecting appropriate medications and management strategies to avoid further hepatic compromise.

  -   Clinical Presentation

The patient, a known alcoholic, exhibited signs of liver failure, including fatigue, jaundice, and abdominal distension, indicative of ascites. Additionally, complaints of bloating and indigestion were reported, consistent with dyspepsia. Laboratory tests revealed elevated liver enzymes, reduced albumin levels, and increased bilirubin, confirming hepatic impairment.

  -   Management Strategy

1. Gastrointestinal Symptom Management:
The patient was treated with an injectable anti-nausea agent, potentially containing mequitazine, to relieve gastrointestinal discomfort. Further medications considered for dyspepsia included:

• Antacids: To neutralize stomach acid and provide rapid relief from bloating.
• Proton Pump Inhibitors (PPIs): For long-term reduction of gastric acid secretion to manage reflux symptoms.
• H2 Receptor Antagonists: For additional acid suppression.
• Prokinetics: To enhance gastric motility and reduce bloating by promoting gastric emptying.
• Simethicone: For alleviation of gas-related bloating.
• Digestive Enzymes: To support digestion, particularly if there was evidence of pancreatic insufficiency due to the patient's alcohol abuse.

2. Considerations for Liver Failure:
Given the compromised hepatic function, careful selection of medications was essential. Drugs that could exacerbate liver injury, such as acetaminophen, were avoided. All prescribed medications underwent dosage adjustments to account for the liver’s reduced capacity to metabolize drugs. PPIs and H2 antagonists were dosed cautiously to avoid hepatic strain.

3. Supplementation:
In patients with chronic alcoholism, thiamine (Vitamin B1) deficiency is common. Therefore, thiamine supplementation was included in the treatment plan to prevent the development of Wernicke’s encephalopathy. Other vitamin and nutrient supplements, especially those in the B-vitamin complex, were considered due to the patient's likely malnourished state.

  -   Conclusion

The patient’s clinical presentation highlighted the complexity of managing gastrointestinal symptoms in the context of liver failure and alcoholism. The use of an anti-nausea agent for symptom relief required careful monitoring of hepatic function and adjustments in dosing of additional medications to ensure that further hepatic injury was prevented. The overall treatment plan incorporated gastrointestinal symptom management, appropriate liver-safe medications, and necessary vitamin supplementation to address the patient’s alcohol-related deficiencies. Further follow-up and close monitoring of liver function were recommended to guide ongoing treatment decisions.

Written on October 24, 2024

Mood Disorder Management in an Elderly Male Patient

  -   Patient Profile

An elderly male patient with intermittent episodes of abrupt behavioral changes has been receiving Ativan® (lorazepam) 1 mg for acute symptom control, along with Amitriptyline 10mg, a tricyclic antidepressant (TCA). The patient exhibits notable fluctuations in response, raising considerations for therapeutic adjustment to better support long-term mood stabilization.

  -   Clinical Considerations

Transitioning from a TCA to a selective serotonin reuptake inhibitor (SSRI) such as Prozac® (fluoxetine) is often indicated when side effects, therapeutic efficacy, or pharmacokinetic interactions require reevaluation. The proposed plan involves discontinuing amitriptyline and introducing fluoxetine at a low dose initially (P1), with a gradual increase after an appropriate washout period to minimize adverse effects.

The overlap of TCAs and SSRIs can pose significant risks, primarily due to the pharmacodynamic and pharmacokinetic interactions between these drug classes. Risks include:

• Serotonin Syndrome: The combination of TCA and SSRI increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by symptoms such as confusion, agitation, rapid heart rate, and elevated blood pressure.
• Cardiovascular Effects: TCAs, particularly in elderly patients, can lead to cardiac arrhythmias. Fluoxetine, a potent inhibitor of CYP2D6, may increase amitriptyline levels, exacerbating these risks.
• Increased TCA Toxicity: CYP2D6 inhibition by fluoxetine can lead to elevated plasma levels of amitriptyline, resulting in enhanced side effects such as anticholinergic toxicity, orthostatic hypotension, and sedation, which are particularly problematic in elderly patients.

  -   Treatment Strategy and Rationale

• Discontinuation of TCA: Amitriptyline should be tapered gradually to allow for a safe washout period, which can help mitigate the risks associated with switching to an SSRI.
• Initiation of SSRI: After an interval post-TCA discontinuation, fluoxetine may be introduced at a low dose, monitoring closely for any adverse effects or symptoms indicative of serotonin syndrome or other SSRI-related side effects.
• Monitoring: Regular monitoring of mood, cardiovascular status, and potential drug interactions is essential throughout this transition, given the patient’s age and risk factors associated with polypharmacy.

Written on November 6, 2024

Ofloxacin Ophthalmic Solution as an Alternative for Otic Use

  -   Patient Profile

A middle-aged male patient presented with ear discharge, indicating the presence of an ear infection. The intended prescription was for an ofloxacin otic solution; however, only the ofloxacin ophthalmic solution was available at this time.

  -   Clinical Considerations

When prescribing an antibiotic solution for ear infections, substituting an ofloxacin ophthalmic solution for an ofloxacin otic solution may be acceptable in certain cases, as both formulations contain ofloxacin, an effective fluoroquinolone antibiotic against pathogens commonly involved in ear infections. However, key considerations are necessary to ensure safe administration:

• Sterility and Formulation: Ophthalmic solutions are produced under sterile conditions for use in sensitive eye tissues, generally ensuring safety for application in the ear as well. While minor differences in pH or formulation may exist between ophthalmic and otic solutions, they are typically safe for otic use in the absence of specific otic preparations.
• Concentration and Dosage: For mild to moderate otitis externa, the standard otic dosing of ofloxacin is 10 drops once daily in the affected ear for 7 days. If using an ophthalmic formulation in the ear, this otic dosing guideline should be followed. In cases of severe infection, a twice-daily application may be recommended at professional discretion.
• Patient Monitoring: Close observation for effectiveness and potential signs of irritation is essential, as the ear canal tissue may respond differently from ocular tissue. Monitoring helps ensure that the treatment is both effective and well-tolerated.
• Pharmacy Consultation: If uncertainty exists regarding concentration equivalency between ophthalmic and otic solutions, consulting a pharmacist can help verify appropriate dosing and ensure safe use in this context.

  -   Dosage Recommendations

For substituting the ofloxacin ophthalmic solution in place of the otic solution, the following dosage guideline is recommended:

• Standard Dosage: 10 drops in the affected ear once daily for 7 days for mild to moderate infections.
• Severe Infection Dosage: 10 drops twice daily, though professional discretion is advised depending on the severity and patient tolerance.

  -   Summary and Guidelines for Safe Administration

The ophthalmic formulation of ofloxacin can be considered for otic use with careful attention to dosage adjustments and patient monitoring. Adhering to standard otic dosing, consulting with a pharmacist if concentration confirmation is needed, and observing patient response are essential steps to ensure effective and safe treatment.

Written in November 11, 2024

Excessive Salivation

  -   Patient Profile

A male patient in his 60s presented with complaints of excessive salivation (sialorrhea). His medical history includes a gastric tumor, diabetes mellitus (DM), and benign prostatic hyperplasia (BPH). The persistent symptom of hypersalivation prompted a comprehensive review of his current medications and underlying health conditions to identify potential causes and appropriate management strategies.

  -   Clinical Considerations

Excessive salivation in this patient may be attributed to several factors, including medication side effects and underlying medical conditions. Potential differential diagnoses and contributing factors include:

• Medication-Induced Sialorrhea: Certain medications can stimulate salivary glands or interfere with normal salivary regulation.
• Neurological Conditions: Although not explicitly stated, neurological impairments can contribute to hypersalivation.
• Gastrointestinal Disorders: The presence of a gastric tumor may influence salivary production through reflex mechanisms.
• Systemic Diseases: Diabetes mellitus can have various neurological and autonomic effects that might impact salivation.

  -   Assessment of Medications and Potential Culprits

A review of the patient’s current medication regimen identified several agents that may contribute to excessive salivation:

• Cholinergic Agents:
  • Pilocarpine (Salagen): Administered at a dose of 5 mg orally three times daily. Typically prescribed for dry mouth, but may cause paradoxical hypersalivation in some patients.
  • Cevimeline (Evoxac): Prescribed at 30 mg orally three times daily for xerostomia, with potential side effects including increased salivation.
• Antipsychotics and Neurological Medications:
  • Clozapine (Clozaril): Initiated at 12.5 mg daily, titrated to a maintenance dose of 300–450 mg/day. Notable for causing significant sialorrhea.
  • Olanzapine (Zyprexa): Administered at 5–10 mg daily, with potential escalation up to 20 mg for severe cases, potentially exacerbating salivation.
• Anticholinesterase Inhibitors:
  • Donepezil (Aricept): Given at 5 mg daily, increased to 10 mg after 4–6 weeks if tolerated. Used for Alzheimer’s disease with possible increased salivation.
  • Pyridostigmine (Mestinon): Administered at 60 mg orally three times daily, with a maximum of 120 mg per dose, primarily for myasthenia gravis, potentially causing hypersalivation.
• Opioids and Pain Medications:
  • Methadone (Dolophine): Prescribed at 5–10 mg orally every 8–12 hours, may contribute to sialorrhea in some patients.
• Other Medications:
  • Ketamine: Used at 0.5–1 mg/kg intravenously for procedural sedation, associated with intraoperative or sedation-related hypersalivation.
  • Valproic Acid (Depakote): Administered as per standard dosing protocols, occasionally linked to sialorrhea as a side effect.

  -   Management Strategy

The management of excessive salivation involves identifying and addressing the underlying causes while providing symptomatic relief. The following strategies are recommended:

• Medication Adjustment:
  • Conduct a thorough review of the patient’s current medications to identify potential contributors to sialorrhea.
  • Consider dose reduction or substitution of offending agents in consultation with relevant specialists, such as a neurologist or psychiatrist.
• Symptomatic Management:
  • Glycopyrrolate: Administered orally at 1–2 mg two to three times daily or sublingually at 0.2 mg intramuscularly/subcutaneously every 4–6 hours as needed. Duration is adjustable based on patient response and tolerance.
  • Atropine Drops: Applied sublingually at a dose of 0.4 mg three times daily. Usage should be reassessed regularly to evaluate efficacy and tolerability.
  • Botulinum Toxin Injections: Considered for persistent cases unresponsive to pharmacological treatments. Typically administered every 3–6 months as required.
• Non-Pharmacological Interventions:
  • Implement behavioral therapies such as speech therapy to manage salivation effectively.
  • Educate the patient on oral hygiene practices to prevent complications associated with excessive saliva.

  -   Patient Monitoring and Follow-Up

Regular follow-up appointments are essential to monitor the effectiveness of the management plan and to make necessary adjustments. Monitoring should include:

• Assessment of salivation levels and patient comfort.
• Evaluation of any adverse effects resulting from medication adjustments or new treatments.
• Monitoring for potential exacerbation of BPH symptoms due to anticholinergic therapies.
• Coordination with specialists to ensure a multidisciplinary approach to the patient’s complex medical history.

Written on November 29, 2024

Difficulty in Urination in an Elderly Female Patient

  -   Patient Profile

An elderly female patient presented with persistent complaints of difficulty in urinating and the necessity to exert force on the bladder during voiding. These symptoms have been progressively worsening, impacting the patient's quality of life and daily functioning. Initial assessments indicated no immediate signs of infection, prompting further investigation into potential underlying causes.

  -   Clinical Considerations

Difficulty in urinating and the need to exert force on the bladder in elderly female patients may stem from a variety of etiologies. Differential diagnoses to consider include pelvic organ prolapse, urethral stricture, bladder dysfunction (such as underactive bladder), neurogenic bladder, urinary tract infections, bladder outlet obstruction, and functional causes related to reduced mobility or cognitive impairment.

Each potential condition presents with distinct pathophysiological mechanisms and requires tailored diagnostic and therapeutic approaches to effectively manage the patient's symptoms and underlying condition.

  -   Treatment Options and Rationale

Based on the clinical presentation and differential diagnoses, several pharmacological interventions may be considered to alleviate the patient's symptoms:

• Anticholinergic Medications: Agents such as Oxybutynin (Ditropan XL) at a dosage of 5–10 mg once daily or Tolterodine (Detrol LA) at 2–4 mg once daily may be prescribed to reduce bladder muscle contractions, thereby decreasing urinary urgency and frequency.
• Beta-3 Adrenergic Agonists: Mirabegron (Myrbetriq) at 25–50 mg once daily can be utilized to relax the bladder detrusor muscle, offering an alternative for patients who may experience side effects from anticholinergics.
• Cholinergic Agonists: In cases of underactive bladder or urinary retention, Bethanechol (Urecholine) at 10–50 mg taken 3–4 times daily may be administered to stimulate bladder muscle contractions and promote effective voiding.
• Estrogen Therapy: For postmenopausal women experiencing atrophic changes contributing to urinary symptoms, topical estrogen formulations such as Vaginal Estradiol (Estrace Cream) 0.5 g administered vaginally 2–3 times per week or Estradiol Vaginal Ring (Estring) inserted every 90 days can be beneficial in improving urethral and vaginal tissue integrity.
• Alpha-Blockers: Although more commonly prescribed in male patients, Tamsulosin (Flomax) 0.4 mg once daily or Terazosin (Hytrin) 1–5 mg once daily may be considered in female patients with suspected functional bladder outlet obstruction to relax smooth muscles of the bladder neck and urethra.
• Antibiotics: If a urinary tract infection is confirmed, appropriate antibiotic therapy such as Nitrofurantoin (Macrobid) 100 mg twice daily for 5–7 days or Trimethoprim/Sulfamethoxazole (Bactrim) 1 DS tablet twice daily for 3–5 days should be initiated.

  -   Further Diagnostic and Treatment Approaches

In addition to pharmacological management, further diagnostic evaluations are recommended to ascertain the underlying cause of the urinary difficulties:

• Pelvic Examination: To assess for pelvic organ prolapse or urethral abnormalities that may contribute to urinary obstruction.
• Urinalysis and Culture: To rule out or confirm urinary tract infections as a potential cause of symptoms.
• Post-Void Residual Volume Measurement: Utilizing bladder ultrasound to determine incomplete bladder emptying.
• Urodynamic Studies: To evaluate bladder function and identify issues related to detrusor activity or bladder outlet obstruction.
• Imaging Studies: Such as ultrasound, CT, or MRI to detect structural abnormalities or masses contributing to urinary difficulties.
• Neurological Assessment: If a neurogenic bladder is suspected, further neurological evaluation and imaging may be necessary.

Non-pharmacological interventions, including pelvic floor therapy and behavioral modifications such as bladder training and lifestyle adjustments, should be considered to complement medical treatment and enhance overall management of urinary symptoms.

  -   Management Strategy

The management plan should be individualized based on the specific diagnosis and patient factors. Key considerations include:

• Medication Initiation: Starting with the lowest effective dose of prescribed medications to minimize potential side effects, particularly in the elderly population.
• Monitoring and Follow-Up: Regular assessment of treatment efficacy and side effects, adjusting dosages as necessary. Monitoring for signs of dry mouth, dizziness, or confusion is essential, especially with anticholinergic agents.
• Non-Pharmacological Therapies: Incorporating pelvic floor exercises and bladder training to enhance urinary function and support pharmacological treatments.
• Specialist Referral: Referral to a urologist or urogynecologist may be warranted for complex cases or when initial management strategies are insufficient.

Written on December 3, 2024

Suspected Panhypopituitarism and Secondary Hypothyroidism (Written November 12, 2024)

Clinical Course Summary:

February 29, 2024 Consultation:

The patient had previously been on levothyroxine 50 mcg HS¹ for hypothyroidism; however, this therapy was discontinued after normalization of thyroid function tests (TFTs) at another facility. Recent laboratory evaluations revealed progressively declining free T4 and total T3 levels, suggesting a central etiology.

• On February 15, 2024 (at an outside hospital), results were: T3: 109.90 ng/dL (normal approx. 80–180 ng/dL), TSH: 0.531 mIU/L (normal approx. 0.4–4.0 mIU/L), and Free T4: 0.57 ng/dL (low; normal approx. 0.8–1.8 ng/dL).
• By February 27, 2024, the patient’s T3 had decreased to 76.7 ng/dL, TSH had increased to 4.31 mIU/L (upper-normal/high), and Free T4 had further decreased to 0.35 ng/dL. Thyrotropin-Binding Inhibitory Immunoglobulin (TBII) was <0.8, and Thyroid Microsomal Antibody (TMAb) was 19.30, suggesting the presence of autoimmune markers, though their clinical significance in this scenario remains unclear.

These changes raised suspicion for panhypopituitarism involving secondary (central) hypothyroidism and possible secondary adrenal insufficiency. To address inadequate cortisol production secondary to ACTH deficiency, it was recommended to initiate hydrocortisone replacement (e.g., hydrocortisone 10 mg in the morning (D)² and 5 mg in the afternoon (S)³). Because central hypothyroidism is driven by pituitary dysfunction rather than thyroid gland failure, levothyroxine dosing must be guided by Free T4 rather than TSH alone. After establishing adequate glucocorticoid coverage, the addition of levothyroxine 0.05 mg DA⁴ was planned for the following day. A reassessment of TFTs after one month was advised to fine-tune the levothyroxine dose.

April 1, 2024 Consultation:

Subsequent follow-up indicated normalization of Free T4 levels. Continuation of the current levothyroxine dosing and maintenance of hydrocortisone at the existing dose was recommended. The patient was advised that the development of hyponatremia or hypotension would suggest inadequate glucocorticoid replacement, potentially necessitating an increase in hydrocortisone dosage. In such circumstances, further endocrine consultation would be warranted.

October 16, 2024 Consultation:

By this time, the patient had stabilized on hydrocortisone (Hysone) 10 mg BM⁶ and levothyroxine (Synthyroid) at 0.05 mg DA⁴ on weekdays (Monday through Friday) and 0.1 mg DA⁴ on weekends (Saturday and Sunday). Continued vigilance for signs of adrenal insufficiency or altered thyroid hormone status was advised. Dose adjustments should be considered if clinical or laboratory abnormalities arise.

Pathophysiology and Clinical Considerations

The patient’s condition is consistent with panhypopituitarism—deficiency in multiple anterior pituitary hormones, including ACTH and TSH. Insufficient ACTH leads to secondary adrenal insufficiency, characterized by inadequate cortisol production. Insufficient TSH secretion causes central (secondary) hypothyroidism, characterized by low Free T4 with an inappropriately normal or low TSH. This scenario differs from primary thyroid disease, wherein TSH would typically be elevated in response to low thyroid hormone levels.

Central adrenal insufficiency predisposes to hypotension and hyponatremia due to compromised cortisol-mediated maintenance of vascular tone, impaired free water excretion, and possible subtle alterations in mineralocorticoid action. Initiation of levothyroxine before ensuring adequate cortisol replacement can exacerbate underlying adrenal insufficiency, precipitating an adrenal crisis. Thus, hydrocortisone therapy must be established prior to or concurrent with levothyroxine initiation.

Mechanisms Behind Hyponatremia and Hypotension

• Hyponatremia: Inadequate cortisol reduces the kidney’s ability to excrete free water, potentially leading to water retention and dilutional hyponatremia.
• Hypotension: Cortisol is essential for maintaining vascular responsiveness to catecholamines. Deficiency leads to diminished peripheral vascular resistance and reduced blood pressure.

Further Management and Follow-Up

1. Hormone Monitoring: Regular measurement of Free T4, serum sodium, and blood pressure is essential. Adjust hydrocortisone and levothyroxine doses based on clinical and laboratory findings.
2. Stress Dosing of Steroids: Infections, surgeries, or other physiological stressors require a temporary increase in hydrocortisone to mimic normal adrenal responses.
3. Evaluation of Other Pituitary Axes: Periodic assessment of gonadotropins, growth hormone (GH)/IGF-1, and prolactin may be warranted, given the suspicion of global pituitary dysfunction.
4. Patient Education (Indirect): Patients should be made aware of the importance of strict adherence to medication regimens and should be counseled to seek medical evaluation if symptoms of cortisol deficiency (fatigue, weakness, hypotension) or inadequate thyroid hormone replacement (weight gain, lethargy, cold intolerance) arise.

---

Laboratory Normal Ranges

*In secondary adrenal insufficiency, cortisol levels may be lower than expected for a given clinical scenario.

Autoimmune Markers (TBII and TMAb)

• TBII (Thyrotropin-Binding Inhibitory Immunoglobulin): Associated with Graves’ disease; can interfere with TSH receptor function.
• TMAb (Thyroid Microsomal Antibody), often TPOAb: Common in autoimmune thyroiditis (e.g., Hashimoto’s). May indicate an autoimmune background, but their presence does not directly alter management of central hypothyroidism and adrenal insufficiency.

Footnotes for Dosing Notation

1. HS: At bedtime (Hora Somni)
2. D: Morning (once daily in the morning)
3. S: Afternoon (once daily in the afternoon)
4. DA: Once daily (Die Ante / Daily Administration)
5. DS: Twice daily (morning and afternoon/evening) if indicated
6. BM: "Breakfast Meal" or "Morning Before Meal"

Primary vs. Secondary Adrenal Insufficiency

Written on November 12th, 2024

Clinical Case Scenario of a Custodial Worker with Respiratory Injury Following Inadvertent Bleach Mixture and Recommended Management Strategies (Written December 17, 2024)

This clinical case scenario examines a custodial worker who developed pulmonary injury after inadvertently mixing bleach with another cleaning agent, leading to the release of hazardous gases. The scenario provides insight into the pathophysiological mechanisms, outlines key management priorities, and discusses preventive measures. The emphasis is placed on understanding the behavior of these gases—such as chlorine, which is heavier than air—and the importance of educating cleaning personnel on safe chemical handling. A supplemental table is provided summarizing common bleach-based mixtures, their resultant toxic gases, associated health hazards, and recommended clinical management.

Introduction

Chemical cleaning agents are widely employed in various occupational settings. When bleach (sodium hypochlorite solution) is inadvertently mixed with incompatible substances such as acids, ammonia, baking soda, or hydrogen peroxide, hazardous reactions may occur. These reactions can generate toxic gases that damage the respiratory tract, leading to acute distress and, in severe cases, life-threatening conditions. The following clinical case scenario is presented to illustrate the complications associated with such exposures, highlight the underlying pathophysiology, and delineate immediate management steps.

Clinical Case Scenario

A 45-year-old custodial worker presented to the emergency department with acute onset of shortness of breath, cough, throat irritation, and chest tightness approximately 15 minutes after mixing bleach with an unidentified cleaning agent in a poorly ventilated storage room. There was notable eye irritation and a burning sensation in the throat. Vital signs indicated tachypnea, mild hypoxia, and wheezing on auscultation. The individual’s baseline health was previously unremarkable, and there were no known pre-existing pulmonary conditions.

Initial assessment revealed that the patient had likely inhaled chlorine-containing fumes. The chlorine gas, heavier than air, had pooled near the ground in the enclosed, low-ventilation environment, increasing the risk of inhalation. Mild cyanosis and persistent lower airway irritation were noted. The patient’s condition illustrated the risk posed to untrained or inadequately informed custodial staff who inadvertently release toxic gases by combining incompatible chemicals.

Pathophysiology of Inhalation Injury

1. Bleach and Vinegar (Acid):

   Mixing bleach with an acid (such as vinegar) liberates chlorine gas. When inhaled, chlorine gas reacts with moisture in the respiratory tract to form hydrochloric acid and hypochlorous acid, directly irritating and chemically burning the mucosa of the airways. This can lead to bronchospasm, increased mucus production, and potential pulmonary edema.

2. Bleach and Ammonia:

   Mixing bleach with ammonia produces chloramine gases. Inhalation of chloramines causes irritation to the eyes, nose, throat, and lungs. Similar to chlorine, chloramines react with pulmonary fluids to form corrosive substances, resulting in inflammation, bronchospasm, and possible acute lung injury.

3. Bleach and Baking Soda (Sodium Bicarbonate):

   While generally less hazardous, combining bleach with baking soda can still cause the release of small amounts of chlorine or related irritants. The primary risk is irritation of the upper airways rather than severe lung damage. Nonetheless, prolonged exposure or high concentrations may still contribute to respiratory discomfort and inflammation.

4. Bleach and Hydrogen Peroxide:

   The mixture of bleach with hydrogen peroxide can generate reactive oxygen species and possibly other irritant compounds. Although less commonly encountered, such mixtures can cause mucosal irritation and mild to moderate respiratory distress.

Management and Preventive Strategies

1. Decontamination and Ventilation:
   • Immediately evacuate the patient to an area with fresh air.
   • Remove any contaminated clothing and flush exposed skin or eyes with copious amounts of water if needed.
2. Supportive Respiratory Care:
   • Administer supplemental oxygen to maintain adequate oxygen saturation.
   • Provide bronchodilators (e.g., nebulized beta-2 agonists) to alleviate bronchospasm.
   • Consider inhaled or systemic corticosteroids to reduce airway inflammation and edema.
   • Monitor for signs of pulmonary edema and acute respiratory distress syndrome (ARDS), offering mechanical ventilation if necessary.
3. Pharmacological Interventions:
   • There is no specific “antidote” for chlorine or chloramine inhalation. Treatment is primarily supportive.
   • If there is suspicion of secondary complications such as methemoglobinemia (rare in these scenarios), agents like methylene blue may be considered.
   • Antibiotics are not routinely indicated unless there is evidence of secondary infection, but prophylactic measures may be considered on a case-by-case basis.
4. Further Monitoring and Care:
   • Continuous cardiorespiratory monitoring to detect early signs of respiratory deterioration.
   • Arterial blood gas analysis, chest imaging, and pulmonary function tests to assess the extent of injury.
   • Admission to a hospital setting for observation if symptoms are severe.
5. Preventive Measures:
   • Educate cleaning personnel on chemical handling and the potential dangers of mixing bleach with other agents.
   • Ensure proper ventilation and avoid confined areas with insufficient airflow.
   • In environments at risk for gas accumulation, instruct personnel to remain at higher ground if heavy, noxious gases are released until the area is cleared.

Written on December 17th, 2024

Attempting Hydrochloric Acid Production from Bleach and Vinegar (Written December 17, 2024)

⚠️ Safety Warning

Combining bleach (commonly containing sodium hypochlorite, NaOCl) with vinegar (acetic acid, CH₃COOH) presents significant hazards. This reaction can generate chlorine gas (Cl₂), a highly toxic substance known to cause severe respiratory distress, eye irritation, and other serious health complications. Engaging in such experiments without proper training, adequate ventilation, specialized equipment, and meticulous safety precautions may result in harmful exposure and potentially fatal outcomes. Adopting this method to produce chlorine gas or hydrochloric acid (HCl) is strongly discouraged.

Chemical Basis of the Reaction

When sodium hypochlorite is mixed with acetic acid, an immediate chemical reaction releases chlorine gas, as illustrated in the simplified equation:

Once formed, chlorine gas introduced into water can yield a mixture of hydrochloric acid (HCl) and hypochlorous acid (HOCl):

Although this indicates a pathway to producing HCl, the resulting hydrochloric acid from such a process is neither reliably controlled nor safely concentrated. Conducting this reaction poses serious difficulties in terms of managing reaction variables and ensuring consistent product purity.

Reasons to Refrain from This Method

1. Toxic Gas Generation: Chlorine gas, formed as an intermediate, is perilous when inhaled and can damage respiratory tissues, cause severe irritation, and potentially lead to long-term health complications.
2. Unpredictable Outcomes: The reaction does not lend itself to easy control. Concentrations of HCl obtained through this route are unpredictable and usually insufficient for practical applications.
3. Significant Safety Risks: Managing concentrated acids demands appropriate personal protective equipment (PPE), corrosion-resistant containers, and comprehensive training. Even minor mishandling can result in chemical burns, spills, and hazardous fumes.
4. Legal and Environmental Considerations: Inappropriate handling and disposal of such chemicals may violate regulations and harm the environment, leading to legal repercussions.

Recommended Alternatives

For processes requiring hydrochloric acid, a more prudent and responsible approach involves obtaining commercially produced HCl solutions from reputable sources. These products are accompanied by safety data sheets (SDS), ensuring proper guidance in handling, storage, and disposal.

Written on December 17th, 2024

Potential Hazards from Common Household Chemical Interactions (Written December 17, 2024)

Household chemicals perform essential functions in cleaning, disinfecting, and maintaining indoor environments. While these products are generally safe when used according to their labels, certain combinations can lead to the unintended formation of highly toxic gases, corrosive compounds, explosive mixtures, or other dangerous byproducts. Such reactions frequently occur when acids, bases, oxidizers, organic solvents, or other reactive substances are mixed, whether purposefully or accidentally. Understanding these hazards, along with the underlying chemical principles and associated health risks, is critical for preventing accidents, safeguarding human health, and protecting the environment.

Common Hazardous Household Substances

Written on December 17th, 2024

Complications During Foley Catheter Exchange (Written December 30, 2024)

-   Patient Profile

An 86-year-old male patient with a history of long-term indwelling Foley catheterization presented for routine catheter exchange. The patient was on oral anticoagulation therapy due to atrial fibrillation. His medical history included benign prostatic hyperplasia (BPH) and controlled hypertension. No prior complications were reported during previous catheterizations.

-   Clinical Presentation

During the routine exchange of the Foley catheter, the patient exhibited significant overall muscle tension instead of the expected relaxation. This involuntary muscle contraction hindered the smooth insertion of the new catheter. Notably, bleeding was observed at the urethral meatus, and the catheter could not be advanced past the prostatic urethra. Following the procedure, the patient had no urinary output for six hours, raising concerns for potential urinary retention or catheter misplacement.

-   Clinical Considerations

Foley catheter exchange in elderly patients, especially those on anticoagulation therapy, poses increased risks of complications such as urethral trauma, bleeding, and false passage creation. Factors contributing to these risks include patient discomfort, anatomical changes like prostatic enlargement, and the anticoagulant effect increasing bleeding tendencies. The absence of urinary output post-exchange necessitates immediate evaluation to rule out catheter obstruction, misplacement, or injury-induced urinary retention.

-   Intervention and Referral

Due to the unsuccessful catheter insertion and the presence of bleeding, the patient was promptly referred to the Emergency Department (ED) with urology on standby for further management. The primary objectives were to establish proper urinary drainage and address any complications arising from the initial exchange attempt.

-   Urological Evaluation and Findings

Upon arrival at the ED, the urology team performed a thorough evaluation. A Foley catheter was reinserted under controlled conditions, but resistance was met at the bulbar urethra, suggesting the creation of a false passage. A false passage occurs when the catheter inadvertently dissects through the urethral wall, creating an unintended tract. In this case, the injury likely occurred in the region of the prostate or bulbar urethra during the initial exchange attempt, possibly exacerbated by the patient’s muscle tension and anticoagulation therapy.

The presence of a false passage increases the risk of urinary extravasation and further trauma. To mitigate the risk of urethral stricture, the urology team advised against changing the catheter for at least one week. This period allows the urethral tissues to heal and reduces the likelihood of scar formation that could lead to narrowing of the urethral lumen.

-   Management and Recommendations

1. Catheter Maintenance:
The newly placed Foley catheter was maintained without further changes for a minimum of one week to prevent urethral stricture and allow healing of the injured tissues.

2. Hemorrhage Control:
During urethral milking, mild hematuria was observed. Given the lack of significant bleeding, compression was deemed unnecessary. The patient was advised to monitor for any signs of worsening hematuria, which would necessitate immediate intervention.

3. Monitoring and Observation:
The patient was closely observed for any signs of acute bleeding or infection. Mild hematuria was expected and deemed acceptable provided there was no progression to severe hematuria.

4. Future Catheter Exchange:
It was recommended to postpone further catheter changes for two weeks, allowing adequate time for the urethral injury to heal and reducing the risk of recurrent trauma or stricture formation.

-   Outcome and Lessons Learned

The Foley catheter was successfully maintained, and urinary drainage was re-established without further complications. The patient did not experience severe hematuria or signs of infection during the observation period. This case underscores the importance of gentle technique during catheter insertion, especially in elderly patients on anticoagulation therapy. It also highlights the need for immediate referral to specialized care when complications arise to prevent further injury and ensure effective management.

-   Timeline of Events

Written on December 30, 2024

Clinical case study: endocrine and infectious considerations in a chronically critically ill female ⚕️ (Written May 12, 2025)

I. Patient overview

A 66‑year‑old woman with quadriplegia and a history of traumatic subdural hemorrhage underwent decompressive craniectomy, subsequent cranioplasty, and ventricular shunt placement. She remains tracheostomized and ventilator‑dependent in a long‑term acute‑care setting. Chronic primary hypothyroidism is treated with oral levothyroxine; physiological‑dose hydrocortisone is co‑administered because combined (central ± primary) adrenal–thyroid axis impairment cannot be excluded. Resuscitation is limited by a do‑not‑resuscitate directive.

II. Recent clinical course 🩺

• Five days ago —new greenish sputum, temperature ≥ 38 °C ➞ broad‑spectrum piperacillin/tazobactam (4.5 g IV q12 h).
• Two days ago —abrupt hypotension (77 / 51 mmHg) without overt fluid loss, emesis, or diarrhea.
• No seizures since levetiracetam initiation; ventriculoperitoneal shunt pressure recently optimized.

III. Endocrine background 🧬

Long‑standing hypothyroidism and possible secondary adrenal insufficiency place the patient at risk for hemodynamic instability during systemic infection. Stress‑dose glucocorticoid requirements may outstrip the current replacement regimen.

IV. Hormonal differentials to evaluate ⚠️

V. Recommended laboratory panel 🧪

• TSH, free T₄, free T₃
• 8 a.m. serum total cortisol and ACTH
• Rapid 250 µg cosyntropin stimulation test (if cortisol < 15 µg dL^‑1)
• Thyroid peroxidase and thyroglobulin antibodies
• Basic metabolic panel (focus on Na⁺, K⁺, glucose)
• Complete blood count, CRP, procalcitonin, serial blood cultures
• Arterial blood gas and lactate if shock persists

VI. Acute therapeutic plan 💊

1. Empiric stress‑dose glucocorticoid—hydrocortisone 50 mg IV every 6 h (consider taper to baseline 15–20 mg day^‑1 oral once stabilized and cosyntropin test normal).
2. Maintain levothyroxine—continue usual oral dose via feeding tube; switch to parenteral route if absorption unreliable.
3. Infection control—continue piperacillin/tazobactam; adjust according to culture results and renal function.
4. Hemodynamic support—fluid resuscitation (balanced crystalloids); norepinephrine if mean arterial pressure < 65 mmHg despite fluids and steroids.
5. Electrolyte correction—treat hyponatremia or hyperkalemia promptly to reduce cardiovascular risk.

VII. Thyroid‑related blood‑pressure patterns during infection

🔽 Hypotension‑predominant states

1. Adrenal crisis (secondary to insufficient cortisol)—usually coexists with hypothyroidism; infection triggers vascular collapse.
2. Myxedema coma—profound vasodilation, low cardiac output, bradycardia.
3. Sick‑euthyroid syndrome—TSH often normal; hypotension driven by sepsis itself rather than thyroid dysfunction.

🔼 Hypertension‑predominant states

1. Thyrotoxicosis / thyroid storm—increased β‑adrenergic tone produces systolic hypertension and wide pulse pressure.
2. Subacute (de Quervain) thyroiditis—transient thyrotoxic phase may elevate blood pressure before a hypothyroid phase ensues.
3. Over‑replacement with levothyroxine—iatrogenic excess can present with isolated systolic hypertension.

VIII. Prognostic reflections 🌟

Early recognition of superimposed endocrine crises in chronically critically ill patients is vital. Empiric stress‑dose steroids are justified when hypotension emerges in the context of infection and known thyroid axis impairment. Concurrent evaluation of thyroid function prevents the under‑ or over‑treatment that can tip the balance toward either refractory shock or hypertensive emergencies. A stepwise diagnostic and therapeutic algorithm, as outlined, supports safe, individualized care.

Written on May 12, 2025

Case Study: Recurrent Esophageal Stricture Managed With Endoscopic Balloon Dilatation (Written May 20, 2025)

Patient Snapshot (minimal identifiers)

Clinical Course

After curative-intent chemoradiation at a tertiary center, the patient developed progressive dysphagia due to radiation-related esophageal narrowing. A percutaneous endoscopic gastrostomy (PEG) was placed for enteral feeding. Despite nutritional support, recurrent dysphagia continues to impair oral intake and quality of life.

Therapeutic Plan

Scheduled intervention: Outpatient endoscopic balloon dilatation (EBD) every 2–3 weeks, starting May 22, 2025, Gastroenterology Clinic, nearby Hospital.

Pre-procedure instructions

• Nil per os after 19:00 h on the day before dilatation.
• Hold oral hypoglycemic agents on the morning of the procedure.

Rationale for Balloon Dilatation

Technique (Standard Approach)

1. Sedation & Preparation – Conscious (midazolam ± fentanyl) or monitored anesthesia care; prophylactic antibiotics if indicated.
2. Endoscopic Assessment – Diagnostic endoscope confirms stricture length, diameter, and excludes fistula or active ulceration.
3. Guidewire Placement – A soft-tip guidewire is advanced across the narrowing under direct vision or fluoroscopy.
4. Balloon Selection & Inflation
   • Length: 4–6 cm; diameter sequence e.g., 6 → 8 → 10 → 12 mm.
   • Inflate with saline/contrast to target pressure (3–6 atm) for 30–60 s; observe mucosal blanching without tearing.
   • Step-up dilatations performed in the same session or over successive visits, depending on resistance and patient tolerance.
5. Post-dilatation Care – Observe 2–4 h; start clear fluids once awake; advance diet as tolerated. PPIs are continued to reduce reflux-related restenosis.

Expected Outcomes

• Immediate dysphagia relief in ≥ 70 % of sessions.
• Median durability 2–4 weeks; hence the planned 2–3 dilatations per month until a stable diameter (≥ 15 mm) is achieved.

Risks & Mitigation

• Mucosal tear/bleeding (< 5 %) – treated with endoscopic hemostasis.
• Perforation (< 1 %) – minimized by incremental diameter strategy and fluoroscopic guidance; requires prompt surgical or stent management if occurs.
• Bacteremia – peri-procedural antibiotics in high-risk patients (e.g., prosthetic valves, uncontrolled infection).

Follow-Up Strategy

Teaching Points

• Balloon dilatation is first-line for benign or post-treatment esophageal strictures; repeat sessions are common and planned.
• Gradual “rule of three” inflation (≤ 3 incremental diameters per session) reduces perforation risk.
• Nutritional optimization and tight glycemic control enhance mucosal healing and reduce infection risk in diabetic oncology patients.

Conclusion

In this 64-year-old post-chemoradiation esophageal-cancer survivor, scheduled endoscopic balloon dilatation offers a minimally invasive, iterative solution for radiation-induced strictures, aiming to restore oral intake and improve quality of life while definitive oncologic management is deferred until functional recovery.

Written on May 20, 2025

Management considerations in a 70-year-old male with malleolar tophaceous gout (Written June 10, 2025)

Abstract

Gout is the most prevalent inflammatory arthropathy in older men. The present clinical vignette describes a septuagenarian with a soft, fluctuant swelling over the right malleolar region, consistent with a gouty tophus. This report summarizes typical extra-articular manifestations of gout and provides an evidence-based framework for pharmacologic management, including recommended dosages and durations appropriate for elderly patients.

Case synopsis

A 70-year-old male with a known history of hyperuricemia reported a gradually enlarging, non-tender, soft mass protruding at the right malleolus (“오른쪽 복숭아뼈 부위 튀어나와있고 말랑하게 만져짐”). Acute inflammatory symptoms were absent at the time of assessment.

Typical gout manifestations beyond the first metatarsophalangeal joint

Tophaceous deposits may develop at various peri-articular and extra-articular sites. Commonly reported locations include:

• Helix and antihelix of the ear
• Olecranon and pre-patellar bursae
• Achilles tendon and other tendinous insertions
• Finger pulps and extensor surfaces of forearms
• Eyelids and, less frequently, nasal bridge

Imaging and pathological reviews consistently identify the olecranon bursa, ear helix, and Achilles tendon as classical sites of extra-articular tophi . Recent radiologic series confirm the predilection for juxta-articular soft tissue and tendinous structures, with first metatarsophalangeal and malleolar regions remaining the most frequent intra-articular sites .

Therapeutic strategy

Management of gout comprises three overlapping pillars: (1) acute flare control , (2) long-term urate-lowering therapy (ULT) , and (3) prophylaxis to prevent flares during ULT initiation . Treatment selection must consider comorbidities common in the elderly (renal impairment, cardiovascular disease, gastrointestinal risk) and potential drug interactions.

1. Acute flare control

*Doses represent common adult regimens; individualization based on renal, hepatic, and cardiovascular status is essential.

2. Urate-lowering therapy (ULT)

Initiation of ULT is indicated in patients with one or more tophi, radiographic damage, or ≥2 flares per year. A treat-to-target approach aiming for serum urate < 6 mg/dL (<5 mg/dL if extensive tophi) is endorsed by major guidelines .

3. Prophylaxis during ULT initiation

Anti-inflammatory prophylaxis should commence at least one week before ULT and continue for 3–6 months or longer if flares persist . Acceptable regimens include colchicine 0.6 mg once or twice daily (preferred in renal sufficiency), low-dose NSAID (e.g., naproxen 250 mg BID), or low-dose prednisone ≤10 mg daily.

Monitoring and follow-up

• Serum urate every 2–5 weeks during titration, then every 6–12 months.
• Renal and hepatic panels at baseline and periodically.
• Blood pressure, weight, and cardiovascular risk assessment.
• Clinical inspection of tophus size; imaging if regression uncertain.

Conclusion

The malleolar swelling described is characteristic of tophaceous gout. Evidence-based pharmacotherapy entails prompt control of acute inflammation followed by appropriately titrated, lifelong urate-lowering therapy, with prophylaxis and vigilant monitoring. Adherence to these principles is expected to resolve tophi, prevent further flares, and preserve joint function in elderly patients.

Conflicts of interest: none declared. This summary is intended for educational purposes and should not replace individualized clinical judgment.

Written on June 10, 2025

Progressive tracheostomy stoma narrowing and granulation in a 60-year-old female: diagnostic and therapeutic considerations (Written June 23, 2025)

I. Introduction

Progressive difficulty in exchanging T-tube cannulas often heralds clinically significant peristomal stenosis or intraluminal granulation. Careful endoscopic assessment is essential to delineate the underlying pathology and to guide an evidence-based, least-invasive intervention pathway.

II. Clinical history

• Patient: Female, 60 years old, long-term tracheostomy with Montgomery T-tube.
• Exchange history: 7.0 mm → 6.5 mm → 6.0 mm cuffs over 14 months; the current 6.0 mm tube passes only with resistance.
• No recent respiratory infection, mild exertional dyspnoea, intermittent peristomal bleeding.

Timeline of cannula exchanges

III. Pathophysiological considerations

Granulation at the mucocutaneous junction develops from chronic friction, tube motion, infection, or foreign-body reaction. Hypergranulation may progressively encroach on the lumen, converting a pliable tract into a rigid stenosis that resists downsizing alone.

IV. Assessment strategy

1. Flexible naso-laryngoscopy

   • Visualises the suprastomal tract and vocal cords.
   • Estimates granulation volume and proximity to the subglottis.

2. Multi-detector CT with virtual bronchoscopy

   • Quantifies residual lumen (cross-sectional area) and defines depth of tracheal involvement.

3. Operative endoscopy

   • Rigid bronchoscopy under general anaesthesia for dynamic sizing, balloon calibration, and immediate intervention if needed.
   • If anatomy permits, conjunctive use of a flexible bronchoscope through the rigid barrel for distal inspection.

V. Therapeutic options

1. Cryotherapy via flexible bronchoscope
   • Applies −80 °C nitrogen or −196 °C nitrous oxide to devitalise granulation with minimal charring.
   • Favourable for circumferential, friable, or vascular lesions.
   • Repeat cycles (5–10 s freeze, 30 s thaw) until blanching occurs.
2. Mechanical debulking under rigid bronchoscopy
   • Microdebrider, sharp-tip modified blade, or cup forceps; adequate airway control and bleeding management required.
3. Adjuncts
   • Topical mitomycin-C (0.4 mg/mL, 2 min) to inhibit fibroblast proliferation.
   • Low-dose steroid ointment around the stoma to reduce inflammatory stimulus.
4. Surgical revision
   Reserved for failure of bronchoscopic techniques or concentric tracheal cartilage collapse.

VI. Proposed management plan

1. Schedule combined rigid–flexible bronchoscopy in an OR setting with standby jet ventilation.
2. Perform circumferential mapping; record stenosis length and diameter.
3. Debulk bulky granulation mechanically; apply cryotherapy to residual bases.
4. Instil mitomycin-C; re-fashion the stoma edges where feasible.
5. Up-size to 6.5 mm T-tube intra-operatively; reassess leak pressure.
6. Plan follow-up endoscopy at 6 weeks; if stable, gradual return to 7.0 mm tube.

VII. Rationale

Cryotherapy offers controlled, superficial tissue destruction with lower risk of airway fire compared with laser or electrocautery, and preserves cartilaginous integrity. Rigid bronchoscopy secures ventilation, affords bimanual manoeuvres, and enables immediate haemostasis when granulation is vascular. Sequential dilation and topical antimitotic agents reduce recurrence rates reported in recent case series.

VIII. Follow-up

• Endoscopic reassessment at 6 weeks and 3 months.
• Peak expiratory flow monitoring at home; prompt review if > 20 % decline.
• Peristomal skin care education to minimise micro-trauma.

IX. Conclusion

Progressive stoma narrowing in long-term tracheostomy warrants early endoscopic evaluation. A combined rigid–flexible approach facilitates definitive diagnosis and safe, staged therapy. Cryotherapy, supplemented by topical antimitotic agents and careful tube sizing, constitutes a pragmatic, minimally invasive strategy with favourable safety and recurrence profiles.

X. 요양급여 의뢰서 (Referral Letter)

수신: ○○○○○ 종합병원 호흡기내과(또는 흉부외과) 교수님 귀하

제목: 요양급여의뢰서 – Flexible Bronchoscopy Cryotherapy 의뢰

환자정보
  • 성명 / 성별 / 연령: ○○○ 여, 60세
  • 기왕력: 장기 기관절개, Montgomery T-tube 사용 중
  • 현재상태: T-tube 교환 시 좁아진 기도 및 육아조직으로 6.0 mm 관도 삽입 곤란, 간헐적 출혈 동반

의뢰 사유
  • 기관절개구 주변의 과육아조직(granulation tissue)으로 인한 기도 협착 완화를 위하여, Flexible bronchoscopy + Cryotherapy 시술이 최선의 비수술적 치료로 판단됨.
  • 시술 중 기도 확보 및 지혈이 용이하며, 연골 손상을 최소화하여 재협착 위험을 줄일 수 있음.

요청 내용
  1. Flexible bronchoscopy 하 Cryotherapy 시술 시행
  2. 필요 시 육아조직 기계적 절제 및 Mitomycin-C 국소 도포
  3. 시술 후 내원 6주·3개월 경과 관찰 계획에 따라 결과 회신 요청

첨부: 최근 기관지내시경 소견, 흉부 CT 영상 사본

위와 같이 의뢰하오니, 환자 진료에 협조해 주시기 바랍니다.

감사합니다.
(발급의사 성명 및 면허번호)

XI. 보호자 설명

본 시술은 기관절개 부위에 과도하게 자라난 육아조직을 −80 °C 이하의 저온으로 냉각하여 괴사시키는 방법입니다. 시술 시간은 약 20–30분이며, 국소·경한 전신 마취 후 시행되어 통증은 최소화됩니다. 조직을 태우지 않아 출혈과 흉터가 적고, 기도 연골을 보존하여 재협착 위험을 낮출 수 있습니다. 시술 당일 또는 익일 퇴원이 가능하며, 6주 뒤 내시경 재평가를 통해 효과를 확인합니다. 환자분의 호흡 곤란 및 반복 출혈을 완화하고, 기존 T-tube를 안정적으로 유지하기 위한 필수 치료이오니 양해와 협조 부탁드립니다.

Written on June 23, 2025

Echo-focused case study of advanced ischemic cardiomyopathy on transthoracic echocardiography (Written April 3, 2026)

This case study intentionally minimizes nonessential patient information and focuses on transthoracic echocardiographic interpretation. The discussion is based on the written report sheet and numeric measurement page rather than direct re-review of cine loops; accordingly, emphasis is placed on the reported data, integrated echo reasoning, and practical study points.

I. Case context and quoted report excerpt

A late-70s man with known ischemic cardiomyopathy and atrial fibrillation underwent advanced transthoracic echocardiography. Rhythm and loading conditions are important in this study because the report also documents tachycardia and very low blood pressure.

Selected report statements

"Dilated LV cavity size (65/57 mm) with reduced LV systolic function (EF = 24% by Simpson's)"

"Akinesia with thinning of base to mid anterior, anteroseptal, inferoseptal wall & entire apex"

"Severe hypokinesia of base to mid inferior, inferolateral, anterolateral wall"

"Loss of A wave d/t A. fibrillation (E/e' 15)"

"Small amount of pericardial effusion (RA side 0.66 cm)"

"Mild pulmonary hypertension (RVSP=42mmHg, RAP=15mmHg) - Dilated IVC( 25.2mm) with plethora"

II. Measurement summary

III. Criteria at a glance

The following thresholds are simplified study aids rather than an exhaustive guideline summary. In this case, rhythm, loading conditions, and integrated interpretation matter greatly.

IV. Structured echocardiographic discussion

1. Left ventricular size and geometry

   The dominant structural abnormality is left ventricular cavity dilatation. LVEDD 64.5 mm and LVESD 57.1 mm are well beyond usual male reference limits. Biplane LV volumes show a dilated ventricle with a markedly increased residual end-systolic volume, which is especially useful when studying advanced systolic failure. Septal and posterior wall thicknesses are not increased, LV mass index is not strikingly elevated, and the relative wall thickness is only 0.21. The geometric pattern is therefore markedly eccentric rather than concentric, fitting chronic ischemic remodeling.

2. LV systolic function and regional wall motion

   Global systolic function is severely reduced, with EF reported as 21.6% by 2D mode and 24.0% by biplane Simpson. The more instructive feature, however, is the wall-motion pattern. The quoted description of akinesia with thinning in the anterior, anteroseptal, inferoseptal, and apical segments strongly favors chronic scarred myocardium rather than transient ischemia alone. Additional severe hypokinesia of the inferior, inferolateral, and anterolateral segments indicates dysfunction extending beyond a narrow focal abnormality. From an echocardiographic perspective, this is a study of severe ischemic substrate and adverse remodeling, not merely a study of low EF.

3. Diastolic findings in atrial fibrillation

   The report appropriately notes "Loss of A wave d/t A. fibrillation." Because atrial fibrillation removes a meaningful transmitral A wave, routine E/A-based grading cannot be used. In this setting, reduced annular e′ velocities, an elevated E/e′ ratio, and short deceleration time become more helpful. Septal e′ is 7.23 cm/s, lateral e′ is 6.95 cm/s, E/e′ is 15.22, and DT is 127 ms. Taken together, these findings support elevated LV filling pressure.

   A further study point is the atrial dataset. LA A-P diameter is 42.4 mm, but the preferred contemporary parameter is LA volume index, and the reported LA volume index is 31.7 mL/m², which is not frankly enlarged. This is a reminder that in atrial fibrillation and advanced cardiomyopathy, filling-pressure assessment should remain multiparametric rather than anchored to a single atrial size value.

4. Mitral regurgitation

   The mitral valve is described as native and slightly thickened, with MR grade I+. Quantitative MR data show PISA radius 0.56 cm, EROA 0.14 cm², and regurgitant volume 17.2 mL. These values are in the mild range. Given the ischemic, dilated, poorly contracting ventricle and the absence of a primary major leaflet lesion in the report, the most plausible mechanism is mild secondary functional MR.

   This portion is useful for study because secondary MR often has a crescentic orifice and nonhemispheric flow convergence. Under those conditions, 2D PISA can underestimate severity. Even with that caveat, the present numerical dataset remains far from the severe MR range.

5. Aortic valve and aortic regurgitation

   The aortic valve is described as senile sclerocalcified, but the hemodynamics do not indicate clinically important stenosis. Peak aortic velocity is 2.03 m/s, mean gradient is 9.4 mmHg, DVI is 0.5, and calculated AVA is 1.66 cm². The integrated conclusion is calcific aortic sclerosis without hemodynamically significant aortic stenosis. In a low-flow, low-EF ventricle, valve area should never be interpreted in isolation from the rest of the Doppler dataset.

   AR is graded as I, while AR pressure half-time is 385.4 ms. That value sits in an intermediate zone and should not be over-read. Severe LV dysfunction, tachycardia, and very low diastolic blood pressure can all shorten AR pressure half-time independently of true regurgitation severity. The integrated report therefore supports mild AR rather than moderate-to-severe AR.

6. Right-sided pressure estimate and venous congestion

   TR is graded as I, and the tricuspid regurgitant velocity is 2.62 m/s. By the simplified Bernoulli equation, this yields an RV-RA gradient of about 27.5 mmHg. Once the assigned RAP of 15 mmHg is added, the estimated RVSP becomes 42.5 mmHg. The educational point is that the elevated RVSP is driven importantly by the high right atrial pressure estimate rather than by a markedly high TR velocity.

   The IVC is 25.2 mm and described as plethoric, which fits elevated systemic venous pressure and congestion. Reported RV basal and mid-cavity dimensions are 30.6 mm and 17.5 mm, which are not enlarged by common RV linear thresholds. Because TAPSE, tissue S′, FAC, and RV strain are not displayed on the sheet, formal RV systolic grading should be withheld.

7. Pericardial and ancillary observations

   The narrative comment states "Small amount of pericardial effusion (RA side 0.66 cm)," which corresponds to a small effusion by usual size convention. Later, the structured field appears to state that no pericardial effusion is present. This internal inconsistency is a useful reporting lesson. The sheet also marks intracardiac mass and thrombus as "Unidentifiable." In a ventricle with extensive apical dysfunction, that wording is important because unidentifiable is not equivalent to absent.

V. Integrated interpretation

Pathophysiologic chain: extensive ischemic scar and LV dilatation → severe global systolic failure → elevated LV filling pressure in atrial fibrillation → mild secondary MR and mild pulmonary pressure elevation → plethoric IVC with elevated RAP.

The echocardiographic picture is most consistent with a ventricle-dominant ischemic remodeling case, not a valve-dominant case. The core message of the TTE is advanced ischemic cardiomyopathy with severe LV systolic dysfunction and secondary hemodynamic consequences.

In integrated form, the study supports the following:

• Marked LV dilatation with eccentric adverse remodeling
• Severely reduced LV systolic function with biplane EF about 24%
• Extensive chronic regional wall motion abnormality with thinning, compatible with prior infarction/scar
• Elevated LV filling pressure in atrial fibrillation
• Mild secondary MR, mild AR, and mild TR
• Calcific aortic sclerosis without significant aortic stenosis
• Mild elevation of estimated RVSP, importantly influenced by elevated RAP and venous congestion
• Probable small RA-sided pericardial effusion if the narrative comment is accepted

VI. Interpretive caveats and reporting lessons

1. Atrial fibrillation and beat selection matter

   Atrial fibrillation with HR 115 bpm makes volumetric, inflow, tissue Doppler, and VTI-based measurements more vulnerable to beat selection. For learning purposes, this is a reminder that matched RR intervals and averaging of multiple representative beats are especially important in AF.

2. Loading conditions materially affect Doppler interpretation

   The documented blood pressure of 65/30 mmHg indicates an extreme loading condition. Such a state can alter AR pressure half-time, modify the visual appearance of regurgitant jets, and complicate interpretation of filling-pressure surrogates. The present case therefore rewards integrated reading more than isolated threshold reading.

3. Aortic valve area should not dominate the stenosis assessment

   In a severely dysfunctional, low-flow ventricle, aortic valve area by itself can invite overinterpretation. Here, the low peak velocity, low mean gradient, and DVI around 0.5 all argue against significant aortic stenosis despite calcific leaflet disease.

4. Right ventricular function is incompletely characterized on the sheet

   RV basal size is not enlarged, but TAPSE, tissue S′, FAC, and RV strain are not reported. Direct image review would be required for a firm RV systolic assessment. The note that "3D were done" is informative, but the decisive values actually shown on the report are the 2D and Doppler values.

5. Unidentifiable and contradictory wording should be taken seriously

   "Intracardiac thrombus: Unidentifiable" is not equivalent to a negative thrombus statement, particularly in a ventricle with severe apical dysfunction. Likewise, the narrative comment of a small pericardial effusion and the later structured entry of no effusion should be reconciled before final sign-out or case discussion.

VII. Suggested teaching impression

Suggested teaching impression: Advanced ischemic cardiomyopathy with marked LV dilatation and severely reduced LV systolic function (biplane EF about 24%), extensive chronic regional wall motion abnormality with wall thinning consistent with prior infarction, elevated LV filling pressure in atrial fibrillation, mild secondary MR, mild AR, mild TR, mild elevation of estimated RVSP with high RAP and plethoric IVC, calcific aortic sclerosis without significant stenosis, and probable small RA-sided pericardial effusion.

VIII. Study pearls

• Wall thinning plus akinesia is a strong clue to chronic scar rather than transient dysfunction alone.
• Atrial fibrillation removes the A wave, so routine E/A-based grading should not be forced.
• LA volume index is preferred over simple A-P diameter for atrial size interpretation.
• AR pressure half-time is load dependent and should not be read in isolation.
• Secondary MR may be underestimated by 2D PISA because the regurgitant orifice is often noncircular.
• RVSP is not determined by TR velocity alone; the RAP estimate can materially change the final value.
• Calcific aortic sclerosis should not be mistaken for significant AS when peak velocity and gradients remain low.
• "Unidentifiable" is not the same as "absent" in thrombus reporting.

Written on April 3, 2026

Internal jugular vein echogenicity on carotid ultrasound (Written June 14, 2025)

I. 원문 전체 인용

경동맥 초음파 케이스 하나 여쭙니다. 고진선처 바랍니다.

경동맥초음파에서 오른쪽은 internal jugular vein가 저렇게 속이 까맣게 깨끗하게 보이는데.


왼쪽 vein는 왜 속에 마치 thrombus가 있는 것처럼 지저분하게 보일까요. 아~주 예전에도 이런 분이 한명 있어서 CT 찍었는데 정상으로 나오더라구요. 오늘 또 이런 한분을 만났는데. 무엇인지요.


초보입니다. 비난말고 한수 알려주시면 감사하겠습니다.

도플러도 올려보라고 하셔서올립니다.

혹시 thrombi 인가해서 compression도 해봤지만 compression도 잘 됩니다.뭘까요. CT 찍어야 할까요.

English Translation

A junior otolaryngologist requests guidance on a carotid ultrasound case. On the right side the internal jugular vein (IJV) appears anechoic and “clean,” whereas on the left side the lumen looks heterogeneous and dirty, mimicking thrombus. A similar-looking patient in the distant past yielded a normal CT angiogram, and a second such patient has just been encountered. Doppler clips were obtained; compression of the vessel is easy. Advice is sought regarding the nature of the finding and whether CT is warranted.

II. Comment-by-comment quotation & discussion

1. 원글의 초음파 스킬이 떨어지는데 기계도 좋지 않아 아티팩트가 많이 생김
   기계탓 , 본인 스킬탓임

   The reply attributes the echogenic debris to combined operator-dependency and limited hardware quality, implying that artefact rather than pathology predominates. Ultrasound of superficial neck vessels is highly sensitive to gain, focus, and probe angulation; sub-optimal settings can seed reverberations and noise that mimic intraluminal material.

2. Doppler 도 해서 올려봐봐

   A request for colour or spectral Doppler emphasises that true thrombus shows absent or dampened flow, whereas spontaneous echo contrast (SEC) retains slow swirling velocities. Doppler interrogation is therefore pivotal to discrimination.

3. flow가 느려서 그런데, 종종 보이는 소견입니다. embolic risk 당연히 올릴수 있는데, 예방적 항응고제 사용해야 하는지에 대해서는 교수들도 의견이 분분하고, 환자 risk factor, 임상 상황 고려 해서 결정 해야 겠죠.

   This opinion introduces SEC as a common, low-flow phenomenon and recognises divergent expert attitudes toward prophylactic anticoagulation. Clinical context and individual risk stratification are framed as decisive.

4. 도플러에 왜 색깔이 없어요? 색깔 봐서는 어딘가 와류 생긴거 같은데.

   Absence of colour fill is questioned. Turbulent vortices (“swirl sign”) often appear colour-mosaic; lack thereof may indicate incorrect pulse-repetition frequency (PRF) or a genuinely stagnant segment.

5. 경정맥 확장, 혈전 차있는거 엄청 심해서 헉하고 대학병원 보내면 아무것도 안하고 돌려보냅니다

   A seasoned clinician notes that markedly “thrombotic”-looking IJVs are often referred but ultimately dismissed by tertiary centres, underlining low positive predictive value when appearances alone trigger escalation.

6. 영상은 영상의에게 믿고 맡기세요

   Imaging interpretation is urged to remain within the expertise of radiologists, hinting that interdisciplinary consultation mitigates misclassification.

7. 도플러 색깔 진짜 없냐?????? … 진짜면 thrombus 맞나본데?? … 그런건 대병에서 책임져야지

   Colour silence is equated with thrombosis; referral obligation is stressed should genuine flow absence be confirmed. The comment again underscores the diagnostic weight of Doppler findings.

8. compression 해봐도 잘 눌러지거든요. thrombi면 안 눌리지 않을까요.

   The original poster highlights full compressibility, favouring SEC or artefact over thrombus. Venous thrombus typically displays partial or absent compressibility in B-mode real-time scanning.

9. thrombus 아닙니다!! blood flow가 느려서 보이는 spontaneous echo contrast로 보입니다.

   A decisive statement labels the finding as SEC. Literature indicates SEC arises from erythrocyte rouleaux in low-shear environments, producing intraluminal smoke-like echoes while maintaining patency.

10. 에휴... 이러고선 영상의들 흉보고 다녔나???

    The reply implicitly criticises non-radiologists who prematurely interpret complex sonograms, advocating humility and specialised training to curb misinformation.

11. IVC→Internal jugular vein… thrombus 맞는것 같고 compression여부는 큰 혈관이라 …

    Confusion between vena cava and jugular anatomy is corrected. The writer maintains a thrombus hypothesis, arguing that displacement within a capacious vein could mask compression findings.

12. 앗 수정했습니다. internal jugular vein 맞습니다.

    The original poster amends the anatomical label, showing responsiveness to peer feedback and reinforcing that precise nomenclature matters in vascular imaging.

13. 오답.

    A terse dismissal underscores the contentious atmosphere and the absence of consensus among contributors.

14. 리플이 이렇게 많이 달려있는데 … 그냥 당연히 보이는 artifact 를 가지고 아무도 얘기를 안해주는건 뭔 상황임… thrombi가 저렇게 생기면 사람 디져요…

    The commenter laments the oversight of artefact, reminding that extensive jugular thrombosis would precipitate severe morbidity. The statement reinforces the need for correlation with clinical status.

15. 네 감사합니다. blood flow가 느려서 보이는 걸로 의견이 모아지는 것 같네요…

    Consensus appearance emerges around low-flow SEC. The poster acknowledges residual curiosity about why left-sided velocities are disproportionately reduced, hinting at haemodynamic asymmetry or extrinsic compression.

16. longi는 artifact라 하더라도 axial에서 보이는것을 artifact라고 넘기면… 참고로 artifact가 많이 보이는것은 사실입니다

    Longitudinal imaging artefact is conceded, yet reliance on a single projection is criticised. Orthogonal views and optimal presets remain obligatory before ruling on pathology.

17. 볼 줄 모르면 하지를 말자.

    A blunt admonition re-emphasises the skill requirement for sonography, contributing to the forum’s pedagogical tone.

18. chylomicron

    An unconventional hypothesis points to lipid-rich chylomicrons entering the systemic circulation via the thoracic duct into the left IJV, potentially generating echogenic speckles.

19. 소화관의 지방흡수를 chylomicron이 림프관을 통해 운반… left jugular vein으로 들어가서 chylomicron이 저렇게 보입니다

    Physiological details are elaborated: intestinal chylomicrons travel via lymphatics to the venous angle, entering predominantly the left IJV. Although imaginative, published Doppler studies rarely implicate chylomicrons in sonographic hyperechogenicity.

20. 그럴듯한데. 진짠가?

    Skepticism appears, illustrating how alternative explanations invite critical appraisal rather than immediate acceptance.

21. Pus 입니다.

    The suggestion of intravascular pus is made, yet without corroborative evidence such as systemic infection, making this interpretation empirically weak.

22. 경동맥초음파인데 정맥은 왜 찍지?

    Scope creep is questioned. Nevertheless, routine carotid studies often visualise adjacent IJVs; incidental venous abnormalities can surface, providing serendipitous diagnostic value.

23. 한번 다른 혈관도 찍어보세요. … 다 정맥 저럴 수 있음.

    The comment proposes comparative scanning of additional venous beds, positing that similar echogenic lumens may be physiologic and encouraging broader pattern recognition.

24. IVJ 막히면 줄줄이 막혀서 symptom있을듯. 혈류는 계속 흐릅니다.

    Clinical logic is applied: extensive jugular occlusion would propagate collateral obstruction and symptoms, yet continuous flow counters major thrombosis.

25. 정상을 정상이라고 이야기하는게 젤 어렵죠

    The final insight encapsulates diagnostic humility: recognising normalcy amid suspicious imaging may be the greatest challenge.

III. Consolidated key topics ☑️

• Spontaneous echo contrast as the leading explanation for swirling, hyperechoic venous content.
• Compression test remains reliable for excluding occlusive thrombus when fully collapsible.
• Colour and spectral Doppler settings (gain, PRF) dictate visualisation of slow flow.
• Artefact sources: excessive gain, reverberation, probe tilt, and sub-optimal hardware.
• SEC versus thrombus risk: potential embolic significance debated; decision-making tailored to patient risk profile.
• Anatomical nuance: left IJV receives thoracic-duct lymph; asymmetry in echogenic content may occur.
• Clinical-imaging correlation is imperative; symptom-free patients seldom harbour critical jugular thrombosis.
• Interdisciplinary consultation with radiology enhances accuracy and avoids over-referral.

IV. In-depth analysis of core ideas

1. Physiology and pathogenesis of spontaneous echo contrast

   SEC arises when shear stress falls below the threshold that maintains homogeneous erythrocyte dispersion. Red-cell aggregation creates discrete ultrasonic interfaces, producing the classic “smoke” appearance. Common settings include congestive heart failure, dehydration, or external compression that reduces venous flow velocity. In the jugular veins, upright posture, Valsalva manoeuvre, or end-expiratory breath-hold can transiently accentuate SEC.

2. Imaging hallmarks separating thrombus from SEC

   Thrombus typically demonstrates fixed echogenicity, non-compressibility, and absent colour flow. SEC, in contrast, exhibits dynamic swirling echoes, remains fully compressible, and reveals slow but present flow when PRF is reduced below ≈ 5 cm/s. Longitudinal cine clips accentuate this mobility difference. A high mechanical-index flash or probe tap will often disperse SEC but not organised thrombus.

3. Artefact recognition and avoidance

   Reverberation from the near-wall interface, side-lobe scatter, and gain overshoot can masquerade as intraluminal debris. Systematic optimisation — depth-specific TGC balancing, focus positioning at mid-lumen, utilisation of tissue harmonic imaging, and orthogonal sweeps — mitigates misleading artefact.

4. When is cross-sectional imaging indicated?

   Computed tomography or MR venography becomes reasonable if compressibility is equivocal, colour flow absent despite technical adjustments, or the patient exhibits neck swelling, neurologic sequelae, unexplained fever, or a hypercoagulable background. In asymptomatic individuals with unequivocal SEC characteristics, cross-sectional studies rarely alter management.

5. Left–right haemodynamic asymmetry

   The left IJV may display slower flow owing to thoracic-duct lymph inflow, a longer intrathoracic course, and occasional extrinsic compression by the common carotid artery or thyroid lobe. These factors, combined with imaging at low heart-rate phases, can accentuate SEC unilaterally.

V. Diagnostic criteria table 📊

Written on June 14, 2025

Clinical Case Study and Scenario Exploration

A Case of D-Shaped Left Ventricle: Recognizing Acute Right Ventricular Failure (Written December 13, 2024)

Abstract

A middle-aged female patient presented with a two-week history of progressive dyspnea and fluid retention. Imaging studies, including chest radiography and computed tomography (CT), revealed severe pulmonary edema, pleural effusion, and ascites. Transthoracic echocardiography identified a D-shaped left ventricle, suggesting acute right ventricular (RV) pressure overload. Despite the absence of a clear underlying cause, such as pulmonary embolism, her hemodynamic status deteriorated rapidly. This case emphasizes the importance of promptly recognizing acute right heart failure and the need for urgent referral when no immediate etiologic factor is identified.

Introduction

Acute right heart failure can be life-threatening, often progressing rapidly and posing management challenges distinct from chronic right-sided dysfunction. While left-sided heart failure is more common and well-characterized, acute right-sided failure demands prompt identification and intervention due to its potential for rapid clinical decline. Echocardiographic evidence of a D-shaped left ventricle strongly suggests RV pressure overload and can serve as an immediate clue to underlying acute right heart stress. This report details a case in which a patient with acute right ventricular failure and a D-shaped left ventricle was urgently referred for advanced care, highlighting the importance of timely diagnosis and management.

Case Presentation

A female patient in her fifth decade of life presented with a two-week history of progressively worsening dyspnea and edema. Prior to admission, she had been receiving care at a non-specialized medical facility, delaying advanced cardiopulmonary assessment. On evaluation, she exhibited severe respiratory distress and systemic congestion. A chest radiograph demonstrated marked pulmonary edema. Additional CT imaging revealed significant pleural effusions and ascites, yet no evidence of pulmonary embolism or other structural cardiopulmonary abnormalities was noted.

Transthoracic echocardiography revealed a characteristic D-shaped deformation of the left ventricle, reflecting interventricular septal shifting due to elevated RV pressure or volume load. Only mild tricuspid regurgitation (grade I) was observed, which does not align with the profound regurgitation typically seen in chronic right-sided failure, thus suggesting an acute process. Despite extensive evaluation, the immediate precipitant of acute RV strain could not be identified.

Given the patient’s severe condition and the rapid progression of symptoms, initial management focused on stabilizing intravascular volume with intravenous diuretics. With the imminent risk of hemodynamic collapse, the patient was urgently transferred to a tertiary care university hospital for further advanced diagnostic evaluation and potential intervention.

---

Key Concepts

• Right Ventricular (RV) Failure: A critical condition where the right ventricle fails to adequately pump blood into the pulmonary circulation.
• D-Shaped Left Ventricle (LV): An echocardiographic sign suggestive of RV pressure overload, altering the normal round shape of the LV into a D-shape due to septal displacement.

Background

Why is Right Ventricular Failure Unique?

• The RV is thinner-walled and more compliant than the LV, making it more sensitive to sudden increases in afterload (e.g., acute pulmonary hypertension).
• Acute RV failure can develop rapidly and may cause severe hemodynamic instability before obvious clinical signs arise.
• Unlike LV failure, which often presents with more recognizable patterns and established etiologies (e.g., ischemic heart disease, hypertensive heart disease), RV failure can be triggered by less common and more elusive conditions, making early recognition challenging.

Pathophysiological Mechanisms Leading to RV Failure:

1. Increased Afterload: Sudden rises in pulmonary arterial pressure (e.g., acute pulmonary embolism, severe acute pulmonary hypertension).
2. Direct Myocardial Injury: Isolated RV infarction, myocarditis predominantly affecting the right heart.
3. Volume Overload: Rapid fluid shifts or conditions causing abrupt RV dilation.
4. External Constraints: Pericardial tamponade or constrictive processes can indirectly compromise RV filling.

Common Etiologies of Acute RV Failure

Note: In this case, PE was ruled out early via CT.

---

Case Presentation (Re-Visited)

Patient Profile:

• A middle-aged female
• Chief complaint: Progressive dyspnea and edema for 2 weeks

Initial Findings:

• Severe Respiratory Distress: Marked shortness of breath, orthopnea
• Imaging:
  • Chest X-ray: Severe pulmonary edema (whited-out lung fields)
  • CT: Significant pleural effusions, ascites, but no pulmonary embolism or mechanical obstruction

Echocardiography Key Finding:

• D-Shaped LV: The interventricular septum bowing into the LV, strongly indicating increased RV pressure/strain
• Minimal Tricuspid Regurgitation: Suggesting this is an acute event, not a long-standing chronic RV failure

Suspected Mechanisms in this Case:

• Acute Pulmonary Hypertension of Unclear Origin: Possibly autoimmune (e.g., Takayasu arteritis) or a rapidly evolving inflammatory process.
• Non-Embolic RV Strain: Given that PE was excluded, other causes of acute RV stress must be considered.

Interpreting the D-Shaped LV

Why the LV Becomes D-Shaped:

• Under normal conditions, the LV cavity is elliptical.
• Increased RV pressure (due to high afterload or volume) pushes the interventricular septum into the LV cavity.
• On the parasternal short-axis view of an echocardiogram, this creates a "D-shaped" appearance rather than the normal circular LV contour.

Implications of a D-Shaped LV:

• Strongly suggests RV pressure overload.
• Often associated with conditions like acute PE, severe pulmonary hypertension, or acute RV decompensation.
• In chronic RV failure, one would expect more pronounced tricuspid regurgitation and RV dilation. The absence of these findings here points towards an acute process.

Differential Considerations in This Case

1. Acute Pulmonary Hypertension (e.g., autoimmune flare):
   • Possibly Takayasu arteritis or another vasculitis causing sudden rise in PA pressures.
   • Systemic autoimmune conditions can suddenly worsen, triggering acute pulmonary vascular changes.
2. Myocardial Process (e.g., Isolated RV Myocarditis):
   • Less common, but possible if inflammatory insults selectively target the RV.
3. Rare Embolic Sources (Non-Thrombotic):
   • Fat or air embolism, though these often have other clinical clues.

Diagnostic and Management Strategies

Initial Diagnostic Approach:

1. Exclude Common Causes First:
   • Pulmonary embolism ruled out by early CT scan.
   • No pericardial effusion or valvular lesion to suggest tamponade or severe valvular dysfunction.
2. Assess Hemodynamics:
   • RVSP ~54 mmHg: Elevated, but not as high as in longstanding severe RV failure, supporting an acute event.
3. Consider Specialized Tests:
   • Autoimmune markers, inflammatory tests.
   • Cardiac MRI or advanced imaging if stable enough.

Initial Management Measures:

• Volume Management:
  • Careful diuresis (e.g., intravenous loop diuretics) to relieve congestion.
  • Avoid aggressive fluid challenges in acute RV failure when pulmonary edema is present.
• Urgent Referral to Tertiary Center:
  • Potential access to advanced hemodynamic support (e.g., ECMO) if the patient deteriorates.
  • A multidisciplinary team (cardiology, pulmonary, rheumatology) to rapidly identify and manage any underlying cause.

Lessons Learned

• Rapid Decompensation Risk:
  • RV failure can worsen quickly. Early recognition is vital.
• D-Shaped LV as a Red Flag:
  • The "D-shape" on echo is a key visual sign indicating RV pressure overload.
• Diagnostic Complexity:
  • Unlike LV failure, which has more common etiologies, acute RV failure often arises from elusive or less typical conditions (e.g., autoimmune flares).
• Timely Transfer to Higher-Level Care:
  • When the diagnosis is unclear but the patient is unstable, prompt escalation of care is crucial.

---

Conclusion

Acute right ventricular failure presenting with a D-shaped left ventricle on echocardiography can present without classic etiologies like pulmonary embolism. In such scenarios, less common causes such as autoimmune-mediated acute pulmonary hypertension must be considered. Rapid recognition, careful volume management, and urgent referral to a tertiary care center for advanced diagnostic and therapeutic modalities are essential to improve patient outcomes.

Written on December 13th, 2024

D-Shaped Left Ventricle in Acute Pulmonary Embolism (Written December 13, 2024)

This work represents a rewritten interpretation of the original case study by Dr. Gabe Alagna (PGY1) and Dr. Lauren McCafferty, MD, intended to enhance understanding and facilitate learning for others while giving full credit to the original authors. A D-shaped left ventricle (LV) is a significant echocardiographic finding frequently observed when right ventricular (RV) pressures escalate. One critical clinical scenario associated with this pattern is acute pulmonary embolism (PE). For those seeking to broaden their understanding of the D-shaped LV in various clinical scenarios, a related case study is available at Intern Ultrasound of the Month: A Sign of Acute Pulmonary Embolism. This case, originally presented by Dr. Gabe Alagna (PGY1) and edited by Dr. Lauren McCafferty, MD (Alagna & McCafferty, 2024), features a 77-year-old female with a history of end-stage renal disease, heart failure, and lung cancer who presented to the emergency department after experiencing sudden unresponsiveness.

During her resuscitation for pulseless electrical activity (PEA) arrest, a cardiac point-of-care ultrasound was performed, revealing distinct echocardiographic findings indicative of acute PE, including marked RV enlargement and free wall hypokinesis with preserved apical contractility (McConnell’s sign). These findings, in conjunction with her underlying malignancy and abrupt hemodynamic deterioration, heightened the suspicion for an acute PE as the underlying cause of her clinical instability.

By reviewing this additional case, readers can gain a more comprehensive perspective on the various presentations and underlying mechanisms of a D-shaped LV. Comparing different etiologies, such as acute pulmonary embolism versus other causes of acute right ventricular failure, enhances the overall understanding of how this echocardiographic sign can manifest in diverse clinical contexts. Exploring multiple cases will aid in recognizing the nuanced differences and similarities, ultimately contributing to more accurate and timely diagnoses in emergency medicine.

This integrative approach underscores the importance of recognizing specific echocardiographic patterns, like the D-shaped LV and McConnell’s sign, within the broader clinical framework. Such recognition facilitates prompt and appropriate therapeutic interventions, thereby improving patient outcomes in acute and often life-threatening situations.

Case Overview

A 77-year-old female with a complex history, including end-stage renal disease, heart failure, and lung cancer, experienced a sudden change in mental status. She became unresponsive while seated, prompting activation of emergency medical services (EMS). Although initially awake during transport, she deteriorated upon arrival at the emergency department (ED) and suffered a pulseless electrical activity (PEA) cardiac arrest. Advanced Cardiac Life Support (ACLS) protocols were initiated. During a brief return of spontaneous circulation (ROSC), a point-of-care ultrasound (POCUS) examination revealed marked RV enlargement and free wall hypokinesis with relatively preserved apical contractility (McConnell’s sign). These findings raised strong suspicion for an acute PE, especially given the patient’s underlying malignancy and abrupt hemodynamic deterioration.

Key Echocardiographic Findings

• McConnell’s Sign:
  Characterized by akinesia or severe hypokinesis of the RV free wall with preserved apical contractility. Although not highly sensitive, it is highly specific for acute PE in the proper clinical context. McConnell’s sign may occasionally appear in RV ischemia unrelated to PE, but such occurrences are rare.
• RV Enlargement and D-Shaped LV:
  The RV-to-LV chamber size ratio often approaches or exceeds 1:1 in significant RV strain. Bowing of the interventricular septum into the LV yields a “D-shaped” appearance on short-axis echocardiographic views, reflecting RV pressure overload.
• Other RV Strain Indices:
  Additional parameters such as tricuspid annular plane systolic excursion (TAPSE) and abnormal septal motion (the “D sign”) support the diagnosis of acute PE when integrated with the entire clinical picture.

Diagnostic Considerations

Table: Key Differences in Echocardiographic Findings Between Acute PE-Related RV Strain and Other Causes

This table illustrates that while several findings may overlap between PE and other etiologies of RV dysfunction, the combination of McConnell’s sign and a D-shaped LV strongly directs attention to acute PE, particularly in the setting of hemodynamic instability and risk factors such as cancer-associated hypercoagulability.

Clinical Impact and Management Strategies

Acute PE spans a broad spectrum of severity, ranging from incidental findings in asymptomatic patients to sudden cardiovascular collapse. Hemodynamically unstable PE, once known as “massive” PE, demands rapid intervention. In this case, the recognition of McConnell’s sign prompted immediate therapeutic decisions. Systemic thrombolysis (IV tPA) was administered during recurrent PEA arrest, leading to ROSC. Subsequent stabilization permitted confirmatory imaging via CT angiography, which demonstrated a saddle PE.

1. Immediate Stabilization:
   Ensure airway patency, adequate oxygenation, and hemodynamic support. Vasopressors, fluids, and, in select cases, mechanical circulatory support can be employed.
2. Echocardiographic Assessment:
   Rapid bedside ultrasound can detect RV dilatation, reduced RV contractility, McConnell’s sign, and septal flattening. These findings guide further diagnostic and therapeutic steps, especially when hemodynamic instability precludes safe transfer for CT imaging.
3. Therapeutic Decision-Making:
   Initiation of anticoagulation is fundamental. In severe cases (e.g., persistent hypotension, recurrent arrest), systemic thrombolysis may be necessary. When systemic therapy is contraindicated or ineffective, catheter-directed therapy or surgical embolectomy might be considered.
4. Long-Term Management:
   After stabilization, a comprehensive diagnostic workup identifies risk factors, such as malignancy or inherited thrombophilia, informing secondary prevention strategies.

Broader Perspectives for Improved Patient Outcomes

While echocardiographic findings drive urgent decision-making, the integration of clinical context is paramount. In patients with cancer, there is an elevated risk for venous thromboembolism, necessitating a high index of suspicion for PE. Early recognition of McConnell’s sign, combined with an understanding of the patient’s comorbidities, can expedite life-saving interventions. Additionally, careful follow-up and consideration of inferior vena cava filters, long-term anticoagulation, and involvement of a multidisciplinary team (cardiology, pulmonology, hematology, and oncology) can improve patient outcomes.

Incorporating advanced imaging techniques, serial echocardiograms, and emerging biomarkers may further refine the diagnostic pathway. Further research and case studies offer insight into the nuanced interpretation of RV strain patterns, allowing for more targeted and individualized therapy.

References

• Alagna, G., MD (PGY1) & McCafferty, L., MD. (2024). Intern Ultrasound of the Month: A Sign of Acute Pulmonary Embolism. University Hospitals Emergency Medicine Residency. Retrieved from: https://www.thelandofem.com/blog/2024/2/26/iusotm-mcconnells-sign-pe
• McConnell MV, Solomon SD, Rayan ME, et al. (1996). Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol, 78(4), 469–473.
• Konstantinides SV, Meyer G, Becattini C, et al. (2019). ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 41(4), 543–603.

This refined summary honors the original work, provides comprehensive echocardiographic and clinical context, and presents additional perspectives, aiding in the prompt recognition and management of acute PE.

Written on December 13th, 2024

Carotid Ultrasound Findings in a 47-Year-Old Patient (Written March 24, 2025)

1. Original Question and Responses

View Original Korean

Question (Korean)

f.47환자인데 우측 CCA 140cm/s ICA는 80cm/s 측정되는데 이걸 어떻게 해석해야하나요?
이상해서 측정을 두번했구요
경화반이나 죽상반 협착소견은 없었습니다
CCA velocity가 비정상적으로 높네요

Responses (Korean)

1. Response 1 (Korean)
   ICA로 가면서 떨어지면 괜찮은거 아닌가요?
   근데 CCA에서 plaque가 없고 IMT가 두껍지 않아도 V 높은 경우가 기저 고혈압이 심하거나
   CCA 탄성이 감소한 경우 아닐까싶은데
   책에보면 수축기 최고속도가 20-40세 100+20m/s, 40-59세 89+17m/s로 나오네요
2. Response 2 (Korean)
   두꺼워 보이면 약주면 될꺼 아냐?
3. Response 3 (Korean)
   책에서는 Peak systolic velocity >125 혹은 130cm/sec이상, PSV(ICA)/PSV(CCA)>=2이상이면 NASCET상 50%이상 협착이라는 군요
4. Response 4 (Korean)
   CCA psv 상승으로 불안하신거같은데.IMT 문제없소. ICA velocity 정상이라서 CCA상승이 큰 문제 없어보이네요. ECA velocity도 문제 없다면 추적검사 해서 체크 해보셔도 될거같네요.
5. Response 5 (Korean)
   중요한 것은 ICA 속도인 것으로 알고 있고, 자세히 알려면 복잡하지만 수축기 최고 속도 ICA 가 125 이상이면 50% ICA가 막혀서 의미있는 협착으로 본다는 정도를 알면 좋을 것 같습니다.

View English Translation

Question (English Translation)

A 47-year-old female patient shows a peak systolic velocity (PSV) of 140 cm/s in the right common carotid artery (CCA) and 80 cm/s in the internal carotid artery (ICA). How should this be interpreted?
The measurements were repeated because the findings seemed unusual.
There was no evidence of plaque or atherosclerotic stenosis.
The CCA velocity appears abnormally high.

Responses (English Translation)

1. Response 1 (English Translation)
   If the velocity decreases in the ICA, perhaps there is no major issue.
   Even without plaque or thick intima in the CCA, high velocity can occur if the patient has severe underlying hypertension or if the CCA has reduced elasticity.
   A reference suggests that peak systolic velocity in individuals aged 20–40 is about 100 ± 20 cm/s, and for those aged 40–59, about 89 ± 17 cm/s.
2. Response 2 (English Translation)
   If it looks thick, wouldn’t giving medication resolve the issue?
3. Response 3 (English Translation)
   According to a reference, if the peak systolic velocity exceeds 125 or 130 cm/s, or if the ratio PSV(ICA)/PSV(CCA) is ≥2, it suggests ≥50% stenosis based on NASCET criteria.
4. Response 4 (English Translation)
   The elevated CCA PSV seems to be a concern, but the intima-media thickness (IMT) is normal. Because the ICA velocity is normal, the elevated CCA velocity does not appear to be a significant problem. If the ECA velocity is also normal, regular follow-up examinations might be sufficient.
5. Response 5 (English Translation)
   The important parameter is the ICA velocity. The details can be complex, but generally, if the ICA peak systolic velocity exceeds 125 cm/s, it implies a 50% ICA blockage that is considered clinically significant stenosis.

2. Explanation, Background, and Analysis

A carotid ultrasound evaluates blood flow in the common carotid artery (CCA), internal carotid artery (ICA), and external carotid artery (ECA). In this particular case, the patient’s CCA peak systolic velocity (PSV) is elevated (140 cm/s) on the right side, whereas the ICA-PSV is 80 cm/s. No plaque or significant intima-media thickening (IMT) is observed.

1. Key Carotid Ultrasound Parameters

   • Peak Systolic Velocity (PSV)
     • Represents the highest velocity of blood flow during systole (heart contraction).
     • Often compared against established normal ranges or thresholds to assess for possible stenosis.
   • Intima-Media Thickness (IMT)
     • Measures the combined thickness of the intima and media layers of the arterial wall.
     • Normal IMT usually indicates minimal atherosclerotic change, but does not fully exclude early disease.
   • PSV Ratios
     • PSV(ICA)/PSV(CCA) is a common index for evaluating the severity of stenosis.
     • Ratios ≥2 often indicate ≥50% ICA stenosis based on certain guidelines (e.g., NASCET).
   • Plaque Assessment
     • B-mode imaging visualizes atherosclerotic plaques or calcifications.
     • Absence of visible plaque greatly reduces the likelihood of significant obstruction.

2. Normal and Abnormal Ranges: PSV, IMT, and Ratios

   Carotid artery velocity and IMT values vary by age, sex, cardiovascular risk profile, and methodology. Table 1 provides approximate reference ranges and classifications for each major carotid segment (CCA, ICA, ECA), including possible differences by sex if reported in certain references. It is important to note that exact cutoffs differ among studies and clinical protocols.

   Parameter	Sex	Normal Range	Mild Abnormality	Moderate Abnormality	Severe Abnormality
   PSV (CCA) (cm/s)	M/F¹	~70–125 cm/s (20–60 yrs) IMT <0.9 mm²	125–140 cm/s	140–180 cm/s	>180 cm/s (especially if plaque present)
   PSV (ICA) (cm/s)	M/F¹	<125 cm/s (IMT <0.9 mm)	125–150 cm/s	150–200 cm/s	>200 cm/s (≥70% stenosis often suspected)
   PSV (ECA) (cm/s)	M/F¹	~60–120 cm/s (IMT <0.9 mm)	120–150 cm/s	150–200 cm/s	>200 cm/s (unusual unless significant disease exists)
   PSV Ratio PSV(ICA)/PSV(CCA)	M/F¹	<2.0 (suggesting <50% stenosis)	2.0–2.5 (possible ≥50% stenosis)	2.5–4.0 (often 60–70% stenosis)	>4.0 (≥70% stenosis likely)
   IMT (mm)	M/F¹	<0.9 mm	0.9–1.1 mm	1.1–1.4 mm	>1.4 mm (considered significantly abnormal)

3. NASCET Criteria and Additional Guidelines

   The North American Symptomatic Carotid Endarterectomy Trial (NASCET) established widely utilized benchmarks for carotid stenosis severity based on angiographic measurements. Ultrasound criteria (PSV, velocity ratios, presence of plaque) have been correlated with these angiographic findings. Frequently cited thresholds include:

   • ICA-PSV ≥125–130 cm/s for ≥50% stenosis
   • ICA-PSV ≥200–230 cm/s for ≥70% stenosis
   • PSV(ICA)/PSV(CCA) ≥2 often suggests ≥50% stenosis
   • PSV(ICA)/PSV(CCA) ≥4 often suggests ≥70% stenosis

   Below is an example summary table correlating Doppler velocity measurements with approximate NASCET-based stenosis grading:

   Stenosis Category (NASCET)	ICA-PSV (cm/s)	PSV(ICA)/PSV(CCA) Ratio	Approx. Luminal Narrowing
   <50%	<125 cm/s	<2.0	Minimal or no significant stenosis
   50–69%	125–230 cm/s	2.0–4.0	Moderate stenosis
   ≥70%	≥230 cm/s	≥4.0	Severe stenosis

   Clinical decisions often rely on Doppler ultrasound findings combined with plaque visualization, patient symptoms, and risk factor status. If ultrasound findings are equivocal or if the patient is symptomatic, additional imaging (CT/MR angiography) may be warranted.

4. Analysis for This Patient’s Findings

   1. Elevated Right CCA-PSV (140 cm/s)
      Slightly above general upper-normal limits. However, no plaque is identified, and IMT is not notably thick.
   2. Normal ICA-PSV (80 cm/s)
      • Well below the typical threshold of 125 cm/s that would suggest ≥50% stenosis.
      • PSV ratio (ICA/CCA) <1.0, far from the ≥2.0 cutoff for significant stenosis.
   3. Absence of Plaque
      Suggests that the high CCA velocity is not due to a focal stenosis or atherosclerosis.
   4. Possible Explanations
      • Hypertension or reduced arterial compliance could elevate flow velocity.
      • Technical Factors: Angle of insonation or sampling location can artificially elevate measured velocities.

5. Recommendations for Clinical Management

   1. Blood Pressure Optimization
      High systemic blood pressure can affect carotid velocities. Ensuring controlled blood pressure is crucial for vascular health.
   2. Risk Factor Modification
      Smoking cessation, lipid management, glycemic control, and a balanced diet can help prevent atherosclerotic progression.
   3. Periodic Ultrasound Follow-Up
      Repeat carotid ultrasound to monitor any changes in CCA-PSV, ICA-PSV, and IMT, especially if cardiovascular risk factors are present.
   4. Further Imaging if Warranted
      In cases of ambiguous ultrasound findings or symptomatic patients (e.g., transient ischemic attacks), CT/MR angiography may be considered to exclude significant stenosis definitively.

3. Detailed Analysis of This Patient’s Condition and Proposed Approach

Below is an expanded discussion that recaps the key question and the main responses (in English), followed by an analysis.

1. Recap of the Key Question (English)

   Question:
   A 47-year-old female patient has a right common carotid artery (CCA) peak systolic velocity (PSV) of 140 cm/s, while the right internal carotid artery (ICA) PSV is 80 cm/s. No plaque or significant intima-media thickening is seen. How should this elevated CCA velocity be interpreted?

2. Recap of the Main Responses (English)

   1. Response 1: Suggests that if the ICA velocity is normal, it might not be a significant issue. Possible explanations for elevated CCA velocity without plaque include severe hypertension or reduced arterial elasticity.
   2. Response 2: Briefly mentions that if the vessel looks thick, medication might help—implying that treatment could be aimed at addressing underlying risk factors.
   3. Response 3: References a standard guideline where PSV >125–130 cm/s and PSV(ICA)/PSV(CCA) ≥2 may indicate ≥50% stenosis.
   4. Response 4: Notes that elevated CCA PSV is not necessarily concerning if the ICA PSV is normal and IMT shows no abnormality.
   5. Response 5: Emphasizes that ICA velocity is the more critical parameter and a threshold of 125 cm/s for ICA PSV is often used to define >50% stenosis.

3. Analysis of the Responses and Proposed Approach

   • Since no plaque or significant intimal thickening is detected, and the ICA velocity (80 cm/s) is comfortably below the ≥125 cm/s threshold, there is no immediate ultrasound evidence of clinically significant stenosis.
   • The elevated CCA-PSV (140 cm/s) may reflect:
     • Underlying hypertension or arterial stiffness.
     • Technical factors during the ultrasound exam (e.g., Doppler angle or sampling error).
   • Because the ICA-PSV is well within normal limits, standard guidelines (including the NASCET-based criteria) do not support a diagnosis of >50% stenosis.
   • Management at this point primarily involves:
     • Ensuring blood pressure control and addressing other cardiovascular risk factors.
     • Follow-up ultrasounds to detect any emerging plaque or changes in velocity over time.
     • Further imaging (CT/MRA) only if new symptoms arise or if velocities/IMT significantly change in follow-up.
   • This approach aligns with the consensus in the responses: the normal ICA flow strongly suggests no hemodynamically significant stenosis at present.

In conclusion, the elevated CCA velocity alone—without plaque, abnormal IMT, or elevated ICA velocity—likely reflects a low-risk situation. Emphasis should be on general cardiovascular risk management and periodic follow-up, rather than invasive intervention.

References

1. Bluth EI, Ultrasound: A Practical Approach to Clinical Problems. Thieme Medical Publishers, 2008.
2. Grant EG, et al. Carotid Artery Stenosis: Gray-Scale and Doppler US Diagnosis—Society of Radiologists in Ultrasound Consensus Conference. Radiology 2003;229(2):340–346.
3. Barnett HJM, Taylor DW, Eliasziw M, et al. Benefit of Carotid Endarterectomy in Patients with Symptomatic Moderate or Severe Stenosis. N Engl J Med 1998;339(20):1415–1425.

Written on March 24, 2025

Ultrasound‑guided evaluation and management of elevated D‑dimer in a long‑term‑care resident (Written April 11, 2025)

Clinical vignette

An 85‑year‑old male resident of a long‑term‑care facility (LTCF) reported progressive exertional dyspnoea. Sputum culture yielded multidrug‑resistant Acinetobacter baumannii (MRAB). Previous episodes of hyperkalaemia had been managed conservatively. The facility possessed point‑of‑care ultrasound (POCUS) but lacked CT and MRI capability.

Three sets of plasma biomarkers were obtained over 48 h:

Values remained mildly but consistently above the upper reference limits for D‑dimer and NT‑proBNP, whereas renal clearance stayed preserved.

Sonographic armamentarium for an elevated D‑dimer

Reference values and graded abnormality thresholds

Abbreviations: RV – right ventricle; LV – left ventricle; TAPSE – tricuspid annular plane systolic excursion; S′ – tissue Doppler systolic velocity; PASP – pulmonary artery systolic pressure; IVC – inferior vena cava; RAP – right‑atrial pressure; S – systolic wave; D – diastolic wave.

Stepwise diagnostic algorithm in a sono‑only environment

Elevated D‑dimer  →  Clinical VTE probability score
                         │
           ┌─────────────┴─────────────┐
           │                           │
   Low / intermediate            High probability
       probability                      │
           │                           │
Compression venous duplex        Duplex + immediate TTE
           │                           │
    ┌──────┴──────┐              ┌─────┴─────┐
    │             │              │           │
Positive       Negative      RV strain   No RV strain
    │             │              │           │
Anticoag.   TTE + LUS        Treat as    LUS ± repeat
(see § 4)       │            presumptive    duplex
           ┌────┴────┐          PE
           │         │
        PE signs   No PE signs
           │         │
    Anticoag.   Re‑evaluate other

Management pathways based on sonographic findings

Guardian consent obtained for IRB-approved clinical research aimed at disseminating better clinical practices in hemodynamics.

Written on April 11, 2025

Interpretation of TTE findings in an 85-year-old gentleman (Written June 20, 2025)

An 85-year-old male underwent TTE to evaluate valvular and ventricular function. Normal reference limits follow contemporary recommendations from the American Society of Echocardiography (ASE), American College of Cardiology (ACC) and European Society of Cardiology (ESC).

1. Novisible thrombi in this study
2. Non-RHD:
suspicious severe AS & mild AR (I/IV) d/t senile sclerocalcified AV c LOM
(AVA=0.70/1.87cm2 by 2D/CE, AVAi=0.43cm2/m2 by 2D, Vmax=2.18m/s,
peak/meanPG=19/11mmHg, AV annulus=25.3mm, SVi=40.1ml/m2)
with post stenotic dilatation of ascending aorta=4.2cm
mild to moderate MS & mild MR (I/IV) d/t thickended MV c MAC
(MVA=1.21cm2 by 2D, MDPG=4.49mmHg)
2. Moderate global hypokinesia of LV
3. Enlarged LA (LAVI=58ml/m2) & RA sizes c reduced global LV systolic fx(EF=45%)
4. Moderate RVP (RVSP=58mmHg)
5. Mobile hyperechoic material(=0.58mm) at annulus of mitral valve
r/o calcium debris
6. indeterminate LV filling pattern

Findings and commentary

• 1. No visible thrombi in this study

  No intracardiac thrombus was visualised. Absence of left-atrial or left-ventricular thrombi is reassuring in an elderly individual with mildly reduced ejection fraction and probable diastolic dysfunction.

• 2. Non-RHD: suspicious severe AS & mild AR (I / IV) due to senile sclerocalcified aortic valve with limited opening motion (AVA = 0.70 / 1.87 cm² by 2-D / continuity, AVA_i = 0.43 cm² m^-2, V_max = 2.18 m s^-1, peak / mean ΔP = 19 / 11 mmHg, annulus 25.3 mm, SVI = 40.1 ml m^-2) with post-stenotic dilatation of the ascending aorta = 4.2 cm
  mild–moderate MS & mild MR (I / IV) due to thickened mitral valve with MAC (MVA = 1.21 cm² by 2-D, mean ΔP = 4.49 mmHg)

  Parameter	Patient	Normal / Guideline threshold	Interpretation
  Aortic Valve Area (2-D)	0.70 cm²	>1.0 cm² (severe < 1.0)	Meets anatomic criterion for severe AS
  AVA indexed (AVAi)	0.43 cm² m-2	>0.6 cm² m-2	Severe (low-flow state suspected)
  Vmax	2.18 m s-1	≥4.0 m s-1 severe	Only mild
  Mean ΔP	11 mmHg	≥40 mmHg severe	Only mild
  Stroke-volume index	40.1 ml m-2	35–65 ml m-2	Low-normal
  Ascending aorta	4.2 cm	<3.7 cm	Mild dilatation
  Mitral Valve Area	1.21 cm²	1.5–1.0 cm² moderate	Moderate MS
  Mean mitral gradient	4.5 mmHg	5–10 mmHg moderate	Low-moderate

  The discordance between a markedly reduced anatomic AVA (0.70 cm²) and a low gradient/velocity raises the possibility of low-flow, low-gradient aortic stenosis or technical under-measurement. Confirmation with Doppler calibration, a dobutamine stress-echo, or computed-tomography calcium scoring is advisable. :contentReference[oaicite:1]{index=1}

  Concomitant mild aortic regurgitation and moderate mitral stenosis, both degenerative in origin, compound the haemodynamic burden. Mild calcific mitral regurgitation (I/IV) is noted.

  Patient aortic-valve metrics versus guideline thresholds
  Parameter	Patient	Mild	Moderate	Severe
  Aortic valve area (AVA)	0.70 cm²	>1.5 cm²	1.0–1.5 cm²	<1.0 cm²
  AVA indexed (AVAi)	0.43 cm² m-2	>0.85 cm² m-2	0.6–0.85 cm² m-2	<0.6 cm² m-2
  Peak velocity (Vmax)	2.18 m s-1	2.0–2.9	3.0–3.9	≥4.0
  Mean pressure gradient	11 mmHg	<20	20–39	≥40

  The markedly reduced anatomic AVA with low gradient and velocity is discordant, suggesting low-flow, low-gradient aortic stenosis or technical under-measurement; confirmation with Doppler calibration, dobutamine stress-echo, or CT calcium scoring is advisable.

  Mitral-valve stenosis classification
  Parameter	Patient	Mild	Moderate	Severe
  Mitral valve area (MVA)	1.21 cm²	>1.5 cm²	1.0–1.5 cm²	≤1.0 cm²
  Mean pressure gradient	4.5 mmHg	<5 mmHg	5–10 mmHg	>10 mmHg

  Mild aortic regurgitation and mild degenerative mitral regurgitation (grade I / IV) accompany the stenotic lesions.

  Relevant equations

  • \( \displaystyle AVA = \frac{A_{\text{LVOT}} \times VTI_{\text{LVOT}}}{VTI_{\text{AV}}} \)
  • \( \displaystyle \Delta P = 4\,V^{2} \)
  • \( \displaystyle SV = A_{\text{LVOT}} \times VTI_{\text{LVOT}}, \;\; SVI = \dfrac{SV}{BSA} \)

• 3. Enlarged LA (LAVI = 58 ml m^-2) & RA sizes with reduced global LV systolic function (EF = 45 %)

  Parameter	Patient	Reference range	Interpretation
  Left-atrial volume index	58 ml m-2	16–34 ml m-2	Severely enlarged
  Ejection fraction (biplane)	45 %	53–73 %	Mildly reduced (global hypokinesia)

  Bi-atrial enlargement likely reflects chronic diastolic loading from valvular stenoses and longstanding pressure overload. The modestly reduced ejection fraction may represent after-load mismatch, myocardial degeneration, or concomitant coronary disease; careful clinical correlation is encouraged.

  Parameter	Patient	Normal	Mildly abnormal	Moderately abnormal	Severely abnormal
  LAVI (ml m-2)	58	<34	35-41	42-48	≥49
  Ejection fraction (%)	45	≥53	41-52	30-40	<30

  Marked bi-atrial dilation reflects chronic diastolic loading from valvular obstruction. The mildly reduced ejection fraction may relate to after-load mismatch, myocardial degeneration or concomitant coronary disease.

• 4. Moderate right-ventricular pressure (RVSP = 58 mmHg)

  RVSP (mmHg)	Classification
  <35	Normal
  35–44	Mild pulmonary hypertension
  45–59	Moderate pulmonary hypertension ← Patient
  ≥60	Severe pulmonary hypertension

  An RVSP of 58 mmHg falls within the moderate range and is most likely secondary to post-capillary (valvular and ventricular) pressure elevation. Right-heart catheterisation remains the reference standard where therapeutic decisions depend upon accurate pulmonary-vascular resistance.

• 5. Mobile hyperechoic material (0.58 mm) at the mitral annulus – rule-out calcium debris

  A small oscillating echo density along the calcified mitral annulus most often represents benign friable calcium or fibrin strands. Infective endocarditis is unlikely given the diminutive size (<1 cm) and absence of independent mobile stalk.

• 6. Indeterminate LV filling pattern

  Transmitral inflow and tissue-Doppler indices were insufficient to categorise diastolic filling. A restrictive or pseudonormal pattern may be masked by rhythm, loading conditions or Doppler alignment. Repeat echocardiography with complete diastolic assessment or cardiac MRI is recommended.

Guardian consent obtained for IRB-approved clinical research aimed at disseminating better clinical practices in hemodynamics.

Written on June 20, 2025

TTE findings and hemodynamic management in an elderly patient following traumatic subdural hemorrhage (Written July 11, 2025)

An 82-year-old male developed epilepsy after recovery from a traumatic subdural hemorrhage (T-SDH). Transthoracic echocardiography (TTE) performed during routine evaluation revealed ischemic myocardial injury and impaired ventricular function, prompting initiation of low-dose carvedilol for blood-pressure (BP) control.

TTE demonstrated an ischemic insult in the left anterior descending (LAD) coronary artery territory with moderate left-ventricular (LV) systolic dysfunction (left-ventricular ejection fraction = 43%); blood pressure was therefore managed with Dilatrend® 3.125 mg, half tablet.

Interpretation of key findings

• Ischemic insult in LAD territory frequently produces anterior-wall hypokinesia, limiting systolic performance and predisposing to heart-failure symptoms.
• LVEF = 43 % lies within the “heart-failure with mildly reduced ejection fraction” (HFmrEF) category, where neurohormonal blockade confers prognostic benefit.
• Moderate systolic dysfunction heightens vulnerability to afterload changes; gentle BP control is therefore warranted.

Rationale for carvedilol (Dilatrend®) 3.125 mg ½ tablet

1. Neurohormonal modulation. Carvedilol antagonises β₁, β₂, and α₁ receptors, attenuating the adrenergic drive that aggravates ischemia and LV remodeling.
2. Mortality benefit in ischemic cardiomyopathy. Clinical trials demonstrate reduced all-cause mortality and rehospitalisation when β-blockers are introduced at low dose and titrated upward in LV dysfunction.
3. Blood-pressure control with vasodilation. The additional α₁ blockade offers gentle peripheral vasodilation, lowering afterload without provoking reflex tachycardia.
4. Low starting dose for frailty. A half-tablet (≈ 1.56 mg) minimises initial bradycardia or hypotension in an elderly, potentially volume-sensitive patient recovering from intracranial pathology.

Suggested up-titration schedule^*

^*Dose escalation contingent on tolerance; slower titration advisable in orthostatic intolerance.

Clinical considerations

• Interaction with antiepileptic therapy: β-blockers rarely lower seizure threshold; careful observation remains prudent.
• Intracranial pressure (ICP): Abrupt hypotension may compromise cerebral perfusion after T-SDH; incremental dosing safeguards cerebral hemodynamics.
• Heart-failure management: Combine carvedilol with guideline-directed agents (e.g., ACE inhibitor, mineralocorticoid-receptor antagonist) as tolerated.
• Follow-up imaging: A repeat TTE at 3- to 6-month interval assists in tracking ventricular recovery or progression.

Guardian consent obtained for IRB-approved clinical research aimed at disseminating better clinical practices in hemodynamics.

Written on July 11, 2025

Transthoracic echocardiography assessment in a 92‑year‑old woman (Written July 29, 2025)

I. Patient background

• Age / Sex: 92‑year‑old female
• Comorbidities: end‑stage renal disease on maintenance hemodialysis, long‑standing hypertension, remote cold cerebrovascular accident

II. Quantitative echocardiographic findings

1. Normal sized cardiac chambers with normal global left‑ventricular systolic function (EF: 67 %).

2. Relaxation abnormality of LV filling pattern (E/e′: 14).

3. Moderate circumferential pericardial effusion without hemodynamic significance:
   • LV posterior: 1.62 cm
   • LV apex: 1.71 cm
   • RV side: 1.77 cm
   • RA side: 0.35 cm

4. Concentric left‑ventricular hypertrophy.

5. Slightly dilated sinus of Valsalva (36 mm) and ascending aorta (37 mm).

III. Guideline‑based evaluation

1. Left‑ventricular size and systolic function

   Parameter	Normal	Patient	Interpretation
   LVEF	≥ 53 % (women)	67 %	Normal
   LV internal dimensions / volumes	Within reference range	Normal by report	No dilation

2. Diastolic function  –  grading criteria

   Criterion	Grade				Patient
   	I (impaired relaxation)	II (pseudonormal)	III (restrictive, reversible)	IV (restrictive, fixed)
   E/A ratio	< 0.8	0.8–2.0	> 2.0	> 2.0	Not provided*
   Average E/e′	< 14	14–15	> 15	> 15	14
   Tricuspid regurgitation Vmax	< 2.8 m/s	> 2.8 m/s	> 2.8 m/s	> 2.8 m/s	Not provided
   LA volume index	< 34 mL/m²	> 34 mL/m²	> 34 mL/m²	> 34 mL/m²	Not provided

   • *Given the reported “relaxation abnormality” and borderline E/e′ of 14, the pattern is most compatible with Grade I (impaired relaxation) with borderline filling pressures.

3. Pericardial effusion size classification

   Maximum separation	Classification	Patient (RV side 1.77 cm)
   < 1.0 cm	Mild	Moderate
   1.0–2.0 cm	Moderate
   > 2.0 cm	Large

   No hemodynamic compromise is documented; therefore, tamponade physiology is absent.

4. Left‑ventricular hypertrophy (LVH)

   IVS / PW thickness	Normal	LVH threshold	Patient	Interpretation
   Posterior wall	< 1.0 cm (women)	≥ 1.1 cm	1.62 cm	Concentric LVH
   Interventricular septum*	< 1.0 cm	≥ 1.1 cm	Not provided

   • *Septal thickness was not included but concentric geometry is inferred from concentric wall thickening and preserved cavity size.
   
   

   Geometry pattern	Left ventricular mass index (LVMI)	Relative wall thickness (RWT)
   Normal geometry	Normal (< 95 g/m² in women, < 115 g/m² in men)	Normal (≤ 0.42)
   Concentric remodeling	Normal (< 95 g/m² in women, < 115 g/m² in men)	Increased (> 0.42)
   Concentric hypertrophy	Increased (≥ 95 g/m² in women, ≥ 115 g/m² in men)	Increased (> 0.42)
   Eccentric hypertrophy	Increased (≥ 95 g/m² in women, ≥ 115 g/m² in men)	Normal (≤ 0.42)

5. Aortic root and ascending aorta dimensions

   Segment	Upper normal (women, age > 40)	Patient	Interpretation
   Sinus of Valsalva	≤ 34 mm	36 mm	Slightly dilated
   Ascending aorta	≤ 35 mm	37 mm	Slightly dilated

IV. Integrated assessment

• The left ventricle demonstrates normal systolic performance with concentric hypertrophy, most likely secondary to long‑standing hypertension and chronic afterload burden associated with hemodialysis.
• Diastolic function is consistent with grade I impaired relaxation, while the E/e′ of 14 suggests borderline elevation of filling pressures; volume status fluctuations inherent to dialysis may influence these parameters.
• A moderate, circumferential pericardial effusion is present without hemodynamic significance; interval surveillance is warranted, particularly given the patient’s uremic milieu.
• The aortic root and proximal ascending aorta are mildly enlarged; dimensions are below thresholds generally considered for surgical or endovascular intervention at this age, yet serial imaging is prudent.

V. Clinical implications

1. Blood‑pressure optimization: Intensify antihypertensive strategy to limit further hypertrophic remodeling and aortic dilatation.
2. Volume management: Coordinate with dialysis team to achieve euvolemia, thereby reducing left‑atrial pressure and diastolic filling pressures.
3. Pericardial effusion monitoring: Repeat echocardiography if new symptoms (dyspnea, orthopnea, hypotension) occur or if an inflammatory etiology is suspected.
4. Serial aortic imaging: Consider annual echocardiographic or computed‑tomographic surveillance; expedite if growth > 3 mm appears within a year.
5. Comprehensive geriatric cardiac care: Continue multidisciplinary follow‑up focusing on frailty, cerebrovascular prevention, and dialysis‑related cardiovascular risk.

VI. Key teaching points

• In elderly dialysis patients, concentric LVH and grade I diastolic dysfunction are prevalent and portend heightened cardiovascular risk despite preserved LVEF.
• E/e′ values from 13–15 inhabit a gray zone; interpretation must integrate clinical volume status, atrial size, and pulmonary pressures.
• Pericardial effusion size alone does not dictate intervention; hemodynamic effect remains the critical determinant.
• Slight aortic dilatation in non‑Marfan, normotensive‑controlled elders is generally observed conservatively unless rapid expansion occurs.

Guardian consent obtained for IRB-approved clinical research aimed at disseminating better clinical practices in hemodynamics.

Written on July 29, 2025

Interpretation of Echocardiography Findings in a Clinical Case (Written September 7, 2025)

I. Case Echocardiography Report (English Translation)

Limited study due to supine position
Tachycardia (around 105 bpm)
Tracheostomy present

1. Grossly small LV cavity size with normal LV systolic function (LVEF = 60–65%).
2. Summation of E/A wave due to tachycardia.

• Poor acoustic window makes it difficult to compare accurately with the previous echocardiogram from May 23, 2023, but the LV cavity size appears reduced (42/29 mm then vs 37/26 mm now).

LVEDD: 36.8 mm
LVESD: 26.3 mm
IVSD: 9.5 mm
PWd: 9.4 mm
LA (AP dimension): 29.9 mm
PASP: 21.0 mmHg

II. Detailed Analysis of Echocardiographic Findings

Technical Limitations and Patient Condition

Limited study due to supine position
Tachycardia (around 105 bpm)
Tracheostomy present

The echocardiogram was technically limited by the patient's condition. The patient remained supine and had a tracheostomy in place, which likely impeded optimal positioning for transthoracic imaging. Additionally, the heart rate was elevated (~105 beats per minute), shortening the cardiac cycles. These factors contributed to suboptimal acoustic windows and reduced image quality, making the study less comprehensive than usual.

Left Ventricular Size and Systolic Function

Grossly small LV cavity size with normal LV systolic function (LVEF = 60–65%).

The study notes a markedly small left ventricular (LV) cavity, while the systolic function remains normal. LVEF (left ventricular ejection fraction) is approximately 60–65%, which falls within the normal range for adults, indicating preserved pumping ability. A small LV cavity size means the internal dimensions of the LV are on the lower end of normal or below normal. This could reflect the patient's body size, low blood volume, or dehydration, or a hyperdynamic state where the heart contracts vigorously. Importantly, despite the reduced chamber size, the normal ejection fraction suggests that the ventricular muscle contractility is intact and the stroke volume is maintained through compensatory mechanisms (such as the higher heart rate).

Diastolic Filling Pattern (E/A Wave)

Summation of E/A wave due to tachycardia.

The report indicates that the early (E) and atrial (A) filling waves on transmitral Doppler have merged into a single summation wave. This is attributable to the tachycardia: at a heart rate of ~105 bpm, the diastolic filling period is so short that the normal two distinct filling phases (early passive filling and late atrial contraction filling) overlap. As a result, it is challenging to separate E and A waves, making it difficult to assess diastolic function in the usual way. Under normal conditions (with lower heart rates), the E/A ratio is evaluated to gauge diastolic function. In this patient, because of E–A fusion, a reliable E/A ratio could not be obtained. It is therefore not possible to determine the diastolic dysfunction grade from this study. For reference, in an adult heart at normal heart rates, an E/A ratio around 1–1.5 is expected in normal diastolic function, whereas values significantly below or above that range suggest diastolic dysfunction (Grade I, II, or III as shown below).

Table: Grading of Left Ventricular Diastolic Dysfunction (Adults)

Comparison with Previous Study

Poor acoustic window makes it difficult to compare accurately with the previous echocardiogram from May 23, 2023, but the LV cavity size appears reduced (42/29 mm then vs 37/26 mm now).

The report compares the current findings with a prior echocardiographic study (performed on May 23, 2023). Due to the poor imaging quality of the current study, an exact side-by-side comparison is limited. However, it is noted that the left ventricular cavity dimensions have decreased since the previous exam. Previously, the LV end-diastolic dimension (LVEDD) and end-systolic dimension (LVESD) were approximately 42 mm and 29 mm, respectively. In the current study, these measurements are about 37 mm (LVEDD) and 26 mm (LVESD). Such a reduction in chamber size over time could be influenced by differences in volume status, measurement technique, or patient condition between the two exams. In a stable clinical scenario, a significantly smaller LV cavity now might suggest the patient has a lower circulating volume or higher sympathetic tone at the time of the exam. It is also possible that the previous study had more optimal imaging, and the current measurements underestimated the true size due to suboptimal visualization.

Other Quantitative Measurements

LVEDD: 36.8 mm
LVESD: 26.3 mm
IVSD: 9.5 mm
PWd: 9.4 mm
LA (AP dimension): 29.9 mm
PASP: 21.0 mmHg

The table below summarizes the key echocardiographic measurements for this patient and compares them to normal adult reference ranges:

As shown above, the patient's cardiac dimensions and pressures are mostly within normal limits, aside from the notably small LV cavity size. The LVEDD is below the typical normal range even for a female patient, which aligns with the qualitative observation of a small LV cavity. The ventricular wall thicknesses (IVS and PW) are in the normal range, indicating no LV hypertrophy. The left atrial size is normal (not enlarged), and the estimated pulmonary artery systolic pressure is also normal, suggesting no evidence of pulmonary hypertension. Overall, aside from the reduced LV chamber size, there are no abnormal structural findings.

III. Clinical Implications and Next Steps

In summary, this echocardiographic evaluation reveals a small left ventricular cavity with preserved systolic function and indeterminate diastolic function due to tachycardia. These findings must be interpreted in the context of the patient's clinical state. Below are possible contributing factors for these echo findings and recommended subsequent steps in management and evaluation.

Potential Contributing Factors

• Low preload or volume status: The small LV dimensions may reflect decreased filling of the heart, as seen with intravascular volume depletion (e.g., dehydration or aggressive diuresis). When the body’s volume status is low, the LV appears smaller because it is not filled to normal capacity.
• Tachycardia: The elevated heart rate shortens diastolic filling time, inherently limiting how much blood the LV can accommodate at end-diastole. This leads to smaller measured LV cavity sizes. The tachycardia also caused the fusion of E and A waves, preventing a standard assessment of diastolic function.
• High contractility (hyperdynamic state): If the patient is in a hyperdynamic circulatory state (for example, due to stress, sepsis, pain, or use of inotropic medications), the heart can contract more vigorously, which often results in a smaller end-systolic dimension and can give the appearance of a very small LV cavity on echocardiography.
• Measurement or imaging factors: Given the suboptimal acoustic window, there is a possibility that the true LV size is slightly larger than measured. Poor visualization can lead to underestimation of chamber dimensions. However, the consistency of measurements and overall appearance still suggest a genuinely small LV in this case.

Recommended Next Steps

• Optimize volume status if needed: Correlate the echocardiographic findings with clinical signs of volume status. If the patient appears volume-depleted (e.g., hypotensive, low jugular venous pressure, poor skin turgor), cautiously increasing intravascular volume (fluid administration) may be considered to see if it leads to improved hemodynamics and possibly a more normal LV size on a follow-up assessment.
• Address the tachycardia: Investigate and manage the cause of the elevated heart rate. If appropriate, rate control (using medications or treating underlying triggers such as pain, agitation, or fever) could be beneficial. Slowing the heart rate would prolong diastolic filling time, which not only can improve the patient’s cardiac output if stroke volume is limited by filling, but also would allow a clearer assessment of diastolic function (separating the E and A waves on Doppler).
• Repeat imaging under better conditions: Once the patient’s condition allows, a repeat transthoracic echocardiogram in a better setting (for instance, with the patient in the left lateral decubitus position to enhance imaging windows and at a controlled heart rate) is advisable. If transthoracic windows remain poor and detailed information is needed, a transesophageal echocardiogram (TEE) could be performed for clearer images. A follow-up study could confirm whether the small LV cavity was transient (due to reversible factors like tachycardia or low volume) or persistent.
• Continue standard care and monitoring: Given that systolic function is normal and there are no signs of elevated filling pressures or pulmonary hypertension, the primary focus should remain on the patient’s overall clinical management. The heart appears structurally and functionally adequate in this study. Ongoing monitoring of cardiac function can be done as needed, especially if there are changes in clinical status. If any new symptoms or signs of cardiac dysfunction arise, further detailed cardiac evaluation should be undertaken.

Written on September 7, 2025

Echocardiographic Findings of Multichamber Enlargement and Pulmonary Hypertension (Written September 7, 2025)

I. Introduction

The following report presents an adult patient’s echocardiographic findings, which are notable for multiple chamber enlargements, preserved left ventricular systolic function, and evidence of pulmonary hypertension. It is written as a case study for a clinical audience ranging from medical trainees to experienced cardiologists. This report will translate the key echocardiography results from the original Korean report into English and provide a detailed interpretation of each finding. No identifiable patient information is included, and the discussion is focused on understanding the clinical significance of the findings, reviewing normal reference ranges (for adults), and outlining the differential diagnosis and recommended next steps in management.

II. Summary of Echocardiographic Findings

1. Enlarged LA (LAVI: 87 mL/m²) with normal global LV systolic function (EF: 70%).
2. Enlarged RA and RV with mildly reduced RV systolic function (FAC: 33%).
3. Moderate pulmonary hypertension (RVSP: 57 mmHg) with IVC plethora (25 mm).
4. Elevated LV filling pressure (E/e′: 13).
5. At least moderate TR (grade II–III/IV) with dilated TV annulus (45 mm) and slightly thickened leaflet.
6. Concentric remodeling of LV.
7. Dilated sinus of Valsalva (39 mm) and ascending aorta (36 mm).

In summary, the echocardiogram (transthoracic echocardiography) reveals severe left atrial enlargement, biatrial and right ventricular enlargement, preserved left ventricular ejection fraction, mild right ventricular systolic dysfunction, and evidence of moderate pulmonary hypertension. Notably, there is significant tricuspid regurgitation with annular dilatation, and the left ventricle shows concentric remodeling consistent with long-standing pressure load. The aortic root is mildly dilated. Table 1 below provides key measurements compared to normal adult reference ranges for clarity:

^*FAC: Fractional Area Change (measurement of RV systolic function)

III. Detailed Interpretation of Findings

A. Left Atrial Enlargement and LV Systolic Function

1. Enlarged LA (LAVI: 87 mL/m²) with normal global LV systolic function (EF: 70%).

The left atrium (LA) is markedly enlarged, as indicated by a left atrial volume index (LAVI) of 87 mL/m². In adults, normal LAVI is ≤ 34 mL/m²; thus, this value represents severe LA enlargement. Such a large LA volume usually reflects chronically elevated left atrial pressure over time, often due to longstanding diastolic dysfunction or other causes of impaired filling. The consequence of severe LA enlargement is significant because it predisposes to atrial fibrillation and other atrial arrhythmias. Despite this enlargement, the left ventricular (LV) ejection fraction is 70%, which is within normal to high-normal range, indicating preserved global LV systolic function. In other words, the pumping ability of the LV is intact, suggesting that the patient’s issues are not due to systolic heart failure but more likely related to diastolic function (filling of the heart). A normal EF with a large LA strongly points toward heart failure with preserved ejection fraction (HFpEF), where the heart’s relaxation is abnormal. It is also worth noting that an EF of 70% can be seen in hyperdynamic states or simply as the upper end of normal; in this context, it confirms that systolic function is not impaired.

B. Right Atrium and Right Ventricle Enlargement; RV Function

2. Enlarged RA and RV with mildly reduced RV systolic function (FAC: 33%).

Both the right atrium (RA) and right ventricle (RV) are enlarged. In a normal adult heart, the RA area is usually less than ~18 cm², and the RV’s basal dimension is typically under 42 mm. Although exact measurements are not listed here, the qualitative description indicates the dimensions exceed those normal limits. RV enlargement often accompanies chronic pressure or volume overload of the right heart. In this case, a likely reason is the elevated pressure in the pulmonary circulation (discussed below) causing strain on the RV, and significant tricuspid regurgitation causing volume overload of the RA.

The RV systolic function is reported as mildly reduced, with a fractional area change (FAC) of 33%. FAC is a percentage that measures how much the RV area decreases from diastole to systole; a normal RV FAC is ≥ 35%. Thus, 33% represents a slight reduction in RV contractile performance. Mild RV dysfunction in the presence of RV dilation suggests that the RV is starting to struggle against increased afterload (pressure in the pulmonary artery) or volume load. However, the dysfunction is only mild at this stage, which means the RV is still compensating relatively well. Monitoring RV function is important, because progressive pulmonary hypertension or ongoing volume overload can further impair the RV over time.

C. Pulmonary Hypertension and IVC Plethora

3. Moderate pulmonary hypertension (RVSP: 57 mmHg) with IVC plethora (25 mm).

The estimated right ventricular systolic pressure (RVSP) is 57 mmHg, which indicates pulmonary hypertension (PH). By echocardiographic criteria, an RVSP above approximately 50 mmHg falls into the moderate range of pulmonary hypertension. (For reference, normal RVSP is typically < 35 mmHg, and values of 35–50 mmHg suggest mild PH, while values above ~50–60 mmHg indicate at least moderate PH.) This RVSP is derived from the tricuspid regurgitation jet velocity on Doppler echocardiography using the modified Bernoulli equation, plus an estimate of right atrial pressure. In this case, the inferior vena cava (IVC) is dilated to 25 mm and noted to be plethoric (full and with poor collapse), which suggests an elevated RA pressure (often ~15 mmHg). The dilated, non-collapsing IVC is an important ancillary sign supporting the presence of pulmonary hypertension and right heart strain. An elevated RA pressure is often seen when there is chronic pressure overload on the right side of the heart.

Moderate pulmonary hypertension in this patient is likely a consequence of left heart pathology (post-capillary pulmonary hypertension). The severely enlarged LA and elevated filling pressures (see finding D) raise pressure in the pulmonary veins, which transmits back to the pulmonary artery, causing increased pulmonary artery pressure. This is known as Group II pulmonary hypertension (pulmonary hypertension secondary to left heart disease). The presence of PH has significant clinical implications: it increases workload on the RV, can lead to symptoms like shortness of breath, and requires investigation into reversible causes or direct management of the underlying cause (in this case, treating the left heart dysfunction). Confirmation of the severity and type of pulmonary hypertension can be pursued with a diagnostic right heart catheterization if needed.

D. Elevated Left Ventricular Filling Pressure (Diastolic Dysfunction)

4. Elevated LV filling pressure (E/e′: 13).

The ratio of early mitral inflow velocity to mitral annular early diastolic velocity (E/e′) is 13. This Doppler index is used to estimate left ventricular filling pressures (i.e., pressure in the left atrium during diastole). In general, an E/e′ ratio above 14 is considered indicative of elevated LV filling pressure, while values between about 8 and 12 are borderline or inconclusive by themselves. An E/e′ of 13 is at the high end of borderline, and given the context of markedly enlarged LA and other echocardiographic features, it strongly suggests that the patient has elevated left-sided filling pressures. In simpler terms, the pressure in the left heart when the ventricle is relaxing is higher than normal.

This finding is consistent with diastolic dysfunction of the LV. When the LV has impaired relaxation or reduced compliance (stiffness), it leads to higher pressure for any given volume of filling, which then transmits to the left atrium. The combination of this E/e′ ratio with the LA enlargement and the tricuspid regurgitation velocity (which contributes to the RVSP) points to at least moderate diastolic dysfunction (often categorized as Grade II diastolic dysfunction, or “pseudonormal” filling pattern, if mitral inflow patterns were analyzed). Essentially, the heart’s filling phase is impaired, corroborating the diagnosis of HFpEF (heart failure with preserved ejection fraction). Recognizing elevated filling pressures is crucial, as it guides therapy (e.g., diuretics, blood pressure control) and helps explain symptoms like exercise intolerance or dyspnea even though EF is preserved.

E. Tricuspid Regurgitation and Tricuspid Valve Changes

5. At least moderate TR (grade II–III/IV) with dilated TV annulus (45 mm) and slightly thickened leaflet.

The echocardiogram indicates at least moderate tricuspid regurgitation (TR), graded roughly as II–III on a scale where I is mild and IV is severe. Moderate TR means a significant amount of blood is leaking back through the tricuspid valve from the right ventricle to the right atrium during systole. The tricuspid valve (TV) annulus is measured at 45 mm, which is dilated well beyond normal. (Typically, a normal tricuspid annulus diameter is around 28–35 mm in adults; an annulus > 40 mm is clearly enlarged.) A dilated annulus often accompanies significant TR, since the valve leaflets can no longer coapt fully when the ring is enlarged. The mention of a slightly thickened leaflet suggests there are some structural changes to the valve leaflets (which could be due to age-related degeneration or other pathology), but no gross malformation is noted.

These findings together point toward functional (secondary) TR rather than primary valvular disease. In functional TR, the valve itself is essentially normal but becomes incompetent due to dilation of the annulus and distortion of the valve geometry, usually from right atrial and right ventricular enlargement. The most common cause for this scenario is pulmonary hypertension or left heart failure leading to volume overload in the right heart. Here, the moderate TR is likely a consequence of the elevated pulmonary pressures (and consequent RV enlargement) discussed above. Moderate TR can contribute to further RA enlargement and signs of systemic venous congestion (like liver congestion or edema) if severe enough. It is an important finding because if TR becomes severe, it can lead to significant morbidity, and interventions (such as surgical tricuspid valve repair or newer catheter-based treatments) might be considered. At the moderate stage, management focuses on treating the underlying cause (reducing pulmonary pressures and venous congestion) and observing if the regurgitation progresses.

F. Concentric LV Remodeling

6. Concentric remodeling of LV.

The left ventricle is described as having “concentric remodeling.” This term indicates that the LV walls are relatively thickened (or the chamber radius is relatively small) without a significant increase in overall LV mass beyond normal. In concentric remodeling, the wall thickness increases as an adaptation to pressure overload, but the LV cavity size is normal and muscle mass is not excessively enlarged (distinguishing it from concentric hypertrophy, where there is an increase in muscle mass as well). This pattern is commonly seen in patients with long-standing hypertension or other conditions that impose chronic pressure load on the heart. Essentially, the heart muscle thickens to make the wall stronger to pump against high pressure.

Concentric remodeling is consistent with the patient’s other findings that suggest hypertensive heart disease. It contributes to diastolic dysfunction because a thicker, less compliant ventricle relaxes and fills less easily. Along with the elevated filling pressures and LA enlargement, the concentric remodeling of the LV further supports the idea that the patient’s cardiac changes are due to chronic pressure overload (likely high blood pressure over time). Management of a patient with concentric remodeling focuses on aggressive control of blood pressure and other risk factors to prevent progression to heart failure or overt LV hypertrophy.

G. Dilated Aortic Root (Sinus of Valsalva) and Ascending Aorta

7. Dilated sinus of Valsalva (39 mm) and ascending aorta (36 mm).

The sinus of Valsalva (the aortic root just above the aortic valve) measures 39 mm, and the ascending aorta measures 36 mm in diameter. These values are mildly elevated above normal expectations for an adult (typical normal upper limits for the aortic root are in the mid-30s millimeter range, varying with age and body size). While different guidelines have slightly different cutoff values, generally an aortic root diameter of around 40 mm or more would be considered dilated. In this case, 39 mm is at the borderline of mild dilatation, and 36 mm in the ascending aorta is also slightly enlarged.

Mild dilation of the aortic root and ascending aorta can be associated with long-standing hypertension (which can cause the aorta to enlarge over time due to the constant high pressure load on the vessel wall). Other causes can include connective tissue disorders (like Marfan syndrome or bicuspid aortic valve with aortopathy), but those typically cause larger degrees of dilation and often at younger ages. There is no indication from the echocardiogram of any aortic valve dysfunction, and the dilation is modest. The clinical approach to a mildly dilated aorta is to ensure optimal blood pressure control and to follow the aortic dimensions over time with serial imaging. Usually, no surgical intervention is indicated until the diameter is significantly larger (for example, ≥ 45–50 mm depending on patient-specific factors and guidelines). Thus, these findings serve as a reminder to manage risk factors and plan follow-up imaging to monitor the aorta for any further enlargement.

IV. Synthesis and Differential Diagnosis

When integrating all of these echocardiographic findings, a unifying theme emerges: the heart shows changes consistent with long-standing pressure overload and diastolic dysfunction, with secondary effects on the right heart. The severe left atrial enlargement, elevated filling pressure, and concentric LV remodeling point strongly toward a chronic hypertensive heart disease picture leading to heart failure with preserved ejection fraction (HFpEF). In HFpEF caused by hypertension (or similar conditions), the thickened LV walls and stiffness elevate the pressure in the left ventricle during diastole, which in turn raises left atrial pressure and causes the left atrium to enlarge markedly. The elevated left-sided pressures transmit to the pulmonary circulation, causing pulmonary hypertension. As a result, the right ventricle faces increased resistance and gradually dilates and weakens slightly, and the tricuspid valve annulus stretches, leading to functional tricuspid regurgitation and right atrial enlargement.

This interconnected pathophysiology is illustrated in the flowchart above. The most likely diagnosis that ties these echo findings together is heart failure with preserved ejection fraction due to chronic hypertension. However, it is important to consider other potential differential diagnoses that could produce a similar echocardiographic profile, such as:

• Restrictive Cardiomyopathy (e.g., Amyloidosis): Infiltrative diseases like cardiac amyloidosis can cause diastolic dysfunction, severe atrial enlargement, and preserved EF. Amyloidosis often leads to thickened ventricular walls (which might be reported as hypertrophy or concentric remodeling) and valvular thickening. It can also cause pulmonary hypertension and right heart failure. In this case, the absence of mention of markedly increased ventricular wall thickness or characteristic tissue features makes hypertension more likely, but a workup for infiltrative disease could be considered if clinical suspicion exists.
• Constrictive Pericarditis: This condition can also present with preserved EF, biatrial enlargement, and pulmonary hypertension. Constrictive pericarditis leads to impaired filling of the heart due to a stiff pericardium, causing elevated filling pressures and dilated atria. However, echo in constriction often shows specific features (like septal bounce or pericardial thickening) which were not noted here. It remains a less likely consideration given the evidence of concentric LV remodeling which points to an intramyocardial cause like hypertension.
• Valvular Heart Disease: Severe mitral valve disease (especially mitral stenosis or regurgitation) can also cause a large left atrium and pulmonary hypertension. In this echocardiogram, there was no mention of significant mitral valve abnormalities, making this unlikely. The tricuspid regurgitation here appears secondary (functional) rather than primary rheumatic disease.

Overall, chronic hypertension leading to diastolic dysfunction and HFpEF is the best fit for this constellation of findings. The differential considerations above would typically be evaluated if the clinical picture or additional data suggested those possibilities (for example, signs of systemic disease for amyloidosis or history of tuberculosis for constrictive pericarditis, etc.).

V. Recommendations and Next Steps

A. Further Diagnostic Evaluation

• Right Heart Catheterization (RHC): Given the echocardiographic evidence of moderate pulmonary hypertension (RVSP ~57 mmHg), a right heart catheterization could be considered to confirm the severity of pulmonary hypertension and to differentiate between pre-capillary and post-capillary causes. In this patient, it is expected to reveal elevated pulmonary artery pressures with an elevated pulmonary capillary wedge pressure (PCWP) consistent with left heart disease. RHC is the gold standard for diagnosing pulmonary hypertension and can guide management, especially if considering advanced therapies for pulmonary hypertension.
• Advanced Cardiac Imaging if Needed: If there is any suspicion of an infiltrative cardiomyopathy (such as amyloidosis) or if precise quantification of cardiac volumes and function is needed, a cardiac MRI could be performed. Cardiac MRI can provide detailed tissue characterization (e.g., late gadolinium enhancement patterns in amyloidosis) and more accurate measurement of ventricular mass and fibrosis. In this case, it would be most useful if non-hypertensive causes for the diastolic dysfunction are being explored.
• Transesophageal Echocardiography (TEE): The current findings were obtained via transthoracic echocardiography. A TEE could be considered if better visualization of certain structures is required. For example, if there were concern about the mechanism of the tricuspid regurgitation or a need to rule out any thrombus in the markedly enlarged left atrium (especially if the patient were in atrial fibrillation and cardioversion or other intervention is planned), TEE would offer superior imaging of those aspects.
• Laboratory and Additional Workup: Depending on clinical context, additional tests could be warranted. For instance, if cardiac amyloidosis is a consideration, laboratory screening (serum and urine electrophoresis for light chains, TTR genetic testing, or bone scintigraphy for transthyretin amyloid) may be indicated. If pulmonary hypertension etiology is in question, evaluating for chronic thromboembolic pulmonary hypertension (CTEPH) with imaging (V/Q scan) or for chronic lung diseases (pulmonary function tests, high-resolution CT) might be pursued. In a patient where left heart disease clearly explains the PH, these may be lower priority, but a thorough evaluation for reversible causes of PH is generally good practice when moderate or severe PH is present.

B. Management Strategies

• Optimize Blood Pressure Control: Strict control of systemic hypertension is crucial. Given the concentric remodeling of the LV and the aortic dilation, aggressive blood pressure management will help reduce further pressure stress on the heart and aorta. This usually involves lifestyle modifications and medications (such as ACE inhibitors, ARBs, or calcium channel blockers), tailored to the patient’s needs.
• Diuretic Therapy for Symptom Relief: If the patient has symptoms of congestion (e.g., shortness of breath, exercise intolerance, peripheral edema), moderate doses of diuretics (such as loop diuretics) can be used to reduce volume overload and lower filling pressures. This can alleviate symptoms by reducing pulmonary congestion and also help decrease the size of the IVC and liver congestion related to the TR.
• Heart Failure With Preserved EF (HFpEF) Management: Beyond diuretics, management of HFpEF includes treating comorbidities and considering newer therapies. Recent evidence supports the use of certain medications like SGLT2 inhibitors in HFpEF to improve outcomes. Other measures include managing atrial fibrillation aggressively (since AF can worsen HFpEF symptoms), and ensuring rate control or rhythm control as appropriate. Exercise training and dietary guidance are also part of comprehensive HFpEF management.
• Rhythm Monitoring and Anticoagulation: Given the severely enlarged left atrium, the risk for atrial fibrillation is high. The patient should be monitored for arrhythmias. If atrial fibrillation is present (or occurs in the future), anticoagulation should be strongly considered according to guidelines (e.g., CHA₂DS₂-VASc score) to prevent thromboembolic stroke, and a rate or rhythm control strategy should be implemented. Even if the patient is currently in sinus rhythm, some clinicians might consider prophylactic anticoagulation in an LA of this size if there are other risk factors, though this remains individualized.
• Management of Tricuspid Regurgitation: The moderate TR in this patient is likely to improve if the pulmonary pressure and volume status are controlled, as it is functional in nature. Medical therapy (diuretics, afterload reduction) may reduce the severity of TR. Regular follow-up echocardiography is warranted to monitor TR severity. If TR progresses to severe and the patient develops refractory symptoms of right heart failure, evaluation for tricuspid valve intervention may be needed. Surgical repair (annuloplasty) is usually considered at the time of other cardiac surgeries, but stand-alone tricuspid surgery or transcatheter tricuspid repair/replacement are emerging options if the TR is severe and symptomatic despite optimal medical therapy.
• Surveillance of Aortic Dimensions: The mild dilation of the sinus of Valsalva and ascending aorta should be periodically monitored. Typically, follow-up imaging (which can be an echocardiogram or a CT/MRI of the aorta) in 6–12 months is reasonable to ensure stability of the aortic size. If the aorta remains stable and below intervention thresholds, ongoing yearly or biennial surveillance may be sufficient. Meanwhile, continued risk factor management (blood pressure control, avoiding smoking, etc.) is recommended to slow any further dilation.

In summary of management, the focus is on treating the underlying causes of the echocardiographic findings: controlling blood pressure and any other factors contributing to diastolic dysfunction, managing heart failure symptoms conservatively, preventing complications like arrhythmias and thromboembolism, and keeping a vigilant eye on the progression of valvular regurgitation and aortic dilation. A multidisciplinary approach involving cardiology (and possibly pulmonary hypertension specialists if needed) will ensure the patient receives comprehensive care.

VI. Conclusion

This case highlights the importance of a systematic approach to echocardiography interpretation and the interconnected nature of cardiac findings. The patient’s echocardiogram demonstrates how chronic pressure overload (likely from hypertension) can lead to a cascade of changes: a stiff left ventricle causing high filling pressures and a large left atrium, which then results in pulmonary hypertension and secondary right heart dilation with tricuspid regurgitation. Despite a normal ejection fraction, the patient exhibits features of heart failure with preserved EF, underlining that heart failure is not solely a disease of reduced systolic function.

For clinicians and trainees, this case reinforces several key points. First, understanding normal reference ranges and grading severity (as provided in the table) is crucial for recognizing the extent of abnormalities. Second, each echocardiographic finding should be interpreted in the broader clinical context — here, the combination of findings paints a clearer picture than any single measurement. Third, the management of such a patient requires addressing the root cause (e.g., hypertension and diastolic dysfunction) and the consequences (pulmonary hypertension and TR) in a coordinated fashion. By following the recommended evaluation and treatment steps, clinicians can improve hemodynamic profiles and potentially the patient’s symptoms and long-term outcomes. Ongoing follow-up with repeat imaging and clinical assessment will be important to monitor changes in chamber sizes, valve function, and aortic dimensions, and to adjust the management plan accordingly.

In conclusion, this echocardiographic case study serves as a comprehensive example of evaluating a patient with multichamber cardiac remodeling and highlights the essential links between imaging findings and clinical management strategies in cardiology.

Written on September 7, 2025

Echocardiographic Assessment of an 87-Year-Old Female (Written October 15, 2025)

I. Patient Background

An 87-year-old female was admitted with a subdural hematoma and required mechanical ventilatory support. During her hospital stay, a comprehensive transthoracic echocardiogram (TTE) was performed to evaluate her cardiac function. Details of her initial cardiovascular status were limited, but the echocardiogram provided important insights into her heart structure and function.

II. Echocardiographic Findings and Interpretation

A. Cardiac Chamber Dimensions and Systolic Function

Note: Normal LV end-systolic dimension depends on overall heart size and ejection fraction.

Interpretation: The left ventricular (LV) walls are at the upper limit of thickness with a mildly increased septal thickness (suggesting borderline hypertrophy). The LV chamber size is normal (diastolic diameter ~53 mm, at the upper normal limit for an elderly female) and systolic function is preserved (ejection fraction ~56%). The LV mass index is elevated, indicating left ventricular hypertrophy (LVH); given the normal relative wall thickness, this hypertrophy is likely an eccentric pattern (possibly related to long-standing pressure and volume load, as seen in hypertension or aging hearts). The left atrium (LA) is significantly enlarged (LA volume index ~50 mL/m², which is markedly above normal), reflecting chronically elevated filling pressures. The ascending aorta is mildly dilated, which can be an age-related degenerative change.

B. Valvular Findings

• Mitral Valve (MV): The mitral annulus is calcified, a common degenerative finding in the elderly. There is only mild mitral regurgitation (MR, Grade I), indicating trivial backflow that is not hemodynamically significant. No significant mitral stenosis is present, as the calcification has not led to any notable narrowing of the valve opening.
• Aortic Valve (AV): The aortic valve shows degenerative changes with leaflet thickening. Doppler measurements indicate mild-to-moderate aortic stenosis. The peak aortic jet velocity is 2.83 m/s and the mean transvalvular pressure gradient is ~22 mmHg. These values are at the upper end of mild AS, approaching the moderate range. The aortic valve area (AVA) was calculated at ~1.12 cm² (by continuity equation), which falls in the moderate stenosis range (normal AVA is 3–4 cm²; severe AS is defined as AVA < 1.0 cm²). Thus, the patient has degenerative aortic stenosis of roughly moderate severity, though with relatively low gradients (likely reflecting her cardiac output at the time of exam).
• Tricuspid and Pulmonary Valves: Only trivial tricuspid regurgitation and pulmonary regurgitation are noted on color Doppler. These trace regurgitant jets are physiologically minimal and not causing any significant volume overload or hemodynamic compromise. The tricuspid valve leaflets themselves appear structurally normal, and there is no indication of tricuspid stenosis.

C. Diastolic Function and Filling Pressures

Interpretation: The mitral inflow pattern shows an impaired relaxation profile. Specifically, the early diastolic filling (E-wave) is slightly lower than the late filling (A-wave), yielding an E/A ratio of ~0.96. In a younger individual, an E/A ratio below 1 would be abnormal, but in this 87-year-old patient it is near the expected range for her age (healthy older adults often have E/A around 0.8–1.0 due to reduced early filling). However, tissue Doppler imaging reveals that the mitral annular relaxation velocities (e') are reduced (septal e' 8.1 cm/s, lateral e' 8.3 cm/s), which is a sign of diastolic dysfunction. The combination of a borderline E/A ratio with low e' velocities and a large LA volume suggests that Grade I–II diastolic dysfunction is present. The E/E' ratio of ~11 is slightly above normal, indicating that left ventricular filling pressures are modestly elevated. This is further corroborated by the enlarged left atrium (an indicator of chronic elevation of filling pressure). Overall, the diastolic function findings reflect a relaxation abnormality (impaired relaxation of the left ventricle) with some evidence of increased filling pressure, consistent with diastolic dysfunction commonly seen in hypertensive heart disease or simply due to advanced age-related myocardial stiffness.

D. Pulmonary Artery Pressure Estimation

Interpretation: The peak tricuspid regurgitation (TR) jet velocity is about 2.97 m/s, which is mildly elevated above the normal upper limit (~2.8 m/s). Using this TR velocity and an estimated right atrial pressure (based on a dilated inferior vena cava of 23 mm with reduced respiratory collapse), the right ventricular systolic pressure (RVSP) is calculated to be approximately 50 mmHg. An RVSP of 50 mmHg at rest suggests the presence of pulmonary hypertension (PH) (normal RVSP is around 20–25 mmHg, and values above ~35–40 mmHg at rest indicate PH). In this patient, the pulmonary hypertension is likely secondary (post-capillary), due to the elevated left heart filling pressures (diastolic dysfunction) and left atrial hypertension transmitted to the pulmonary circulation. There may also be contributions from any underlying pulmonary pathology or the effects of positive pressure ventilation, but the chronic LA enlargement points to left-sided heart disease as a major factor.

III. Clinical Impression and Recommendations

Summary Impression: This echocardiographic assessment of an elderly patient demonstrates preserved left ventricular systolic function with moderate left ventricular hypertrophy. The most notable valvular lesion is degenerative aortic stenosis of mild-to-moderate severity, which, at present, does not cause severe obstruction but will require monitoring. The mitral valve shows calcification with only mild regurgitation and no significant stenosis. Importantly, there is clear diastolic dysfunction (impaired relaxation) of the left ventricle, as indicated by the filling pattern and enlarged left atrium. This has led to moderately elevated pulmonary artery pressures (reflecting secondary pulmonary hypertension likely due to left-heart diastolic pressures). Overall, the findings are consistent with the cardiac effects of long-standing hypertension and aging: a stiff hypertrophied left ventricle, mild valvular degenerative changes, and resultant pulmonary pressure elevation.

Recommendations: In light of these findings, the following considerations are advised for management and follow-up:

1. Maintain optimal blood pressure control to reduce left ventricular afterload. This may help slow further hypertrophy and alleviate diastolic filling pressures, given the likelihood of underlying hypertension contributing to the LVH and diastolic dysfunction.
2. Monitor for any symptoms of aortic stenosis (such as exertional dizziness, chest pain, or dyspnea). Although the aortic stenosis is only moderate, symptom development would prompt re-evaluation by cardiology. In the absence of symptoms, routine follow-up echocardiography (for example, annually or biannually) can be considered to track progression of the stenosis.
3. Manage the patient’s diastolic heart function through careful volume status control and heart rate management. Avoiding fluid overload and tachycardia will help prevent heart failure symptoms, since the ventricle has impaired relaxation and relies on adequate filling time and normal volume load.
4. Address the pulmonary hypertension indirectly by treating the underlying diastolic dysfunction and optimizing lung health. This includes ensuring good management of any pulmonary conditions (to minimize any additional pulmonary arterial pressure elevation) and maintaining adequate oxygenation, especially if the patient remains on ventilatory support. If the pulmonary hypertension is predominantly due to left heart factors, improving those will in turn reduce the strain on the right heart.
5. Be vigilant for the development of atrial fibrillation or other atrial arrhythmias, as the markedly enlarged left atrium predisposes to such rhythm disturbances. If atrial fibrillation occurs, appropriate rate/rhythm control and anticoagulation (considering stroke risk) should be implemented in accordance with guidelines.
6. Coordinate care between neurology and cardiology as the patient recovers from the subdural hematoma. Any interventions or rehabilitation plans should take into account her cardiac status (for example, ensuring cardiovascular stability during physical therapy and understanding that her exercise tolerance might be limited by the moderate aortic stenosis and diastolic dysfunction).

Overall, this case highlights how an elderly patient with neurological issues also has significant cardiac findings on echocardiography. A comprehensive, multi-disciplinary approach is warranted to manage her cardiovascular health in concert with her neurological recovery, always with attention to gentle and cautious management given her advanced age and combined conditions.

Guardian consent obtained for IRB-approved clinical research aimed at disseminating better clinical practices in hemodynamics.

Written on October 15, 2025

Felson's Roentgenology

This study note has been carefully crafted as an educational tool, presenting key concepts from Felson's Principles of Chest Roentgenology: A Programmed Text (3rd edition, 2006) by Lawrence R. Goodman. The content has been refined and reorganized through a personal study process, with the assistance of AI tools, to ensure clarity, professional tone, and logical flow. The note not only summarizes essential concepts but also fills in gaps and upgrades the logic, making it easier to understand and reference.

More

Radiographic Projections: AP, PA, Lateral, and Oblique Chest X-ray Views (Chapter 1)

Chest radiography is a cornerstone of diagnostic imaging, offering crucial insights into the thoracic cavity. Multiple projections—including Anterior-Posterior (AP), Posterior-Anterior (PA), Lateral, and Oblique views—are employed to optimize diagnostic accuracy. Each projection possesses distinct geometric features that influence magnification, sharpness, and the apparent position of thoracic structures. This document presents an integrated, hierarchical discussion of these views, emphasizing technical considerations and clinical implications.

Comparison of AP and PA Chest X-rays

1. Overview and Positioning

   • PA View: The patient faces the detector, with the X-ray source positioned behind. This positioning is often the standard in outpatient and routine inpatient settings, assuming the patient can stand or sit upright.
   • AP View: The patient’s back is against the detector, with the X-ray source in front. This view is commonly used for supine or bedridden patients, such as those in intensive care units.

2. Image Sharpness and Magnification

   Two key principles in radiographic geometry—object-detector distance and object-source distance—govern image sharpness and magnification:

   • Sharpness

     • Structures are sharper when closer to the detector.
     • In the PA view, the heart and lungs lie nearer to the detector, minimizing geometric unsharpness.
     • In the AP view, the heart is farther from the detector, resulting in slightly reduced edge definition.

   • Magnification

     • Magnification increases when structures are closer to the X-ray source.
     • The AP view tends to enlarge the cardiac silhouette because the heart is closer to the source.
     • The PA view keeps the heart and mediastinum nearer to the detector, reducing magnification and yielding a more anatomically accurate representation.

3. Diaphragm Position

   The right hemidiaphragm is typically higher than the left due to the underlying liver. This positional difference remains consistent in both AP and PA views, although respiratory phase and body habitus can subtly influence diaphragm contour.

4. Perceived Cardiac Size

   • AP View: The heart appears larger because of the shorter distance between the heart and the X-ray source.
   • PA View: The heart silhouette is less magnified, facilitating more reliable assessment of cardiomegaly and mediastinal contours.

The Left Lateral View

1. Purpose and Positioning

   The Left Lateral view is frequently performed alongside the PA projection to provide additional information on the anterior-posterior dimension of thoracic structures.

   • The patient’s left side is placed against the detector (cassette).
   • The X-ray source is positioned to the right of the patient.

2. Effect on Nodule Appearance

   • A nodule located on the right side of the thorax appears slightly larger in the Left Lateral view because it is farther from the detector and nearer to the X-ray source.
   • Conversely, left-sided nodules are closer to the detector and thus experience less magnification, appearing closer to true size.

3. Diagnostic Value

   • Provides depth localization of lesions suspected on the PA view.
   • Helps distinguish lesions in the anterior, middle, or posterior compartments of the thorax.

Combining PA and Oblique Views

1. Rationale for Additional Views

   When a lesion is detected on a PA radiograph but overlaps with other structures, anterior oblique projections (e.g., Right Anterior Oblique [RAO] or Left Anterior Oblique [LAO]) can help determine whether the lesion lies in the anterior or posterior thoracic region.

2. Identifying Anterior vs. Posterior Lesions

   Anterior Lesions (e.g., breast tissue, pectoralis muscle) tend to move laterally on an anterior oblique view relative to the thoracic cage. Posterior Lesions (e.g., scapular lesions, paravertebral masses) tend to move medially on an anterior oblique view.

   Lesion Location	Direction of Movement in Anterior Oblique View	Clinical Examples
   Anterior	Moves laterally	Breast, pectoralis muscle
   Posterior	Moves medially	Scapula, spine, paravertebral lesions

3. Clinical Application

   This shift on oblique views enables a more precise localization of lesions. Soft tissue shadows from breasts, pectoralis muscles, or scapulae can thus be distinguished from true pathological findings.

Effect of Expiration on Chest X-rays

1. Lung Appearance

   • Expiration reduces lung volume, increasing lung density on the radiograph.
   • The diaphragm appears elevated, potentially obscuring or compressing portions of the lung fields.
   • This can simulate pathology (e.g., consolidation or effusion) if the phase of respiration is not considered.

2. Cardiac Silhouette

   • The heart may appear larger in expiration due to the elevated diaphragm and reduced thoracic volume.
   • This effect can mimic or exaggerate cardiomegaly, underscoring the importance of using full inspiration when feasible.

3. Best Practice

   Performing chest X-rays during deep inspiration generally produces optimal lung expansion, a more accurate cardiac silhouette, and improved visualization of the pulmonary vasculature.

Written on January 7, 2025

Cross-Sectional Imaging Techniques for the Thorax (Chapter 2)

Cross-sectional imaging has revolutionized thoracic diagnostics by providing detailed visualization of the lungs, mediastinum, vascular structures, and surrounding tissues. Common modalities include Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Ultrasound (US). Each modality has specific strengths, limitations, and optimal clinical applications. This document presents an integrated discussion of imaging planes, image interpretation, characteristic features of different modalities, and considerations for selecting the best imaging technique.

Imaging Planes: Axial, Sagittal, Coronal, and Oblique

1. Axial (Transverse) Plane

   Oriented horizontally, dividing the body into superior (upper) and inferior (lower) parts.

   Chest CT images are conventionally viewed as if looking up from the patient’s feet (i.e., from below). The patient’s right side appears on the left side of the image.

2. Sagittal Plane

   Divides the body into right and left portions.

   Useful for assessing anterior-to-posterior relationships within the thorax, such as the position of mediastinal masses relative to the sternum or vertebral column.

3. Coronal Plane

   Splits the body into anterior (front) and posterior (back) segments.

   Aids in evaluating the lungs and mediastinal structures in a frontal perspective.

4. Oblique Plane

   Any plane that deviates from the standard axial, sagittal, or coronal orientations.

   Employed to better delineate lesions or structures that follow complex trajectories (e.g., vascular or bronchial abnormalities).

Computed Tomography (CT) of the Chest

1. Basic Principles

   CT imaging uses X-rays and computer processing to generate cross-sectional slices. Structures can be evaluated based on their Hounsfield Unit (HU) measurements, which quantify tissue density.

   Hounsfield Scale (Approximate Ranges)

   Tissue / Structure	HU Value	Comments
   Air (e.g., pneumothorax)	~ –1000	Most radiolucent
   Lung Parenchyma	~ –800	Varies with inflation and pathology
   Fat	~ –80 to –120	Subcutaneous or mediastinal fat
   Water	0	Reference point
   Muscle	~ +40	Soft tissue density
   Bone	~ +350 (can range +300 to +1000)	Highly radiodense

   • Higher HU values indicate denser (more radiopaque) tissues (e.g., bone).
   • Lower (negative) HU values represent radiolucent (less dense) tissues or air (e.g., lung, pneumothorax).

   Window Settings in Chest CT

   • Lung Window: Optimized to visualize parenchymal detail (e.g., nodules, consolidation, interstitial patterns).
   • Mediastinal Window: Highlights mediastinal structures (e.g., heart, vessels, lymph nodes).
   • Bone Window: Enhances bony detail for detecting rib fractures or focal lesions in vertebrae.

2. Advantages of CT

   • Rapid imaging with high spatial resolution, ideal for evaluating lung parenchyma, pleural abnormalities, and acute chest conditions.
   • Widely available and relatively straightforward to perform in most clinical settings.
   • Enables three-dimensional reconstructions for surgical planning or further analysis.

3. Disadvantages of CT

   • Ionizing Radiation exposure.
   • Frequent use of iodinated contrast agents, which may pose risks for nephrotoxicity or allergic reactions in susceptible individuals.

4. Common Indications and Contraindications for Chest CT

   Indications	Contraindications / Cautions
   Detection and characterization of pulmonary nodules, masses, or infections Evaluation of pulmonary embolism (CT pulmonary angiogram) Assessment of traumatic injuries to the chest wall, lungs, or mediastinum Preoperative mapping for thoracic surgery	Severe contrast allergy or renal insufficiency (when contrast is indicated) Concerns about radiation dose in pregnant patients or pediatric populations Need to avoid iodinated contrast in hyperthyroidism or specific drug interactions

Magnetic Resonance Imaging (MRI) of the Chest

1. Basic Principles

   MRI relies on the interaction of hydrogen nuclei with strong magnetic fields and radiofrequency pulses. Different pulse sequences emphasize various tissue properties such as fat, fluid, and blood flow. Unlike CT, MRI does not use Hounsfield Units; instead, tissue characterization is based on signal intensities, primarily determined by T1 and T2 relaxation times.

2. T1-Weighted vs. T2-Weighted Imaging

   Sequence	Key Characteristics	Common Applications
   T1-Weighted	Fat appears bright (high signal) Water/Fluid appears darker Good anatomical detail	Evaluating normal anatomical structures Assessing fat-containing lesions Post-contrast imaging (e.g., gadolinium enhancement)
   T2-Weighted	Fluids (e.g., edema, cystic lesions) appear bright Fat may appear relatively darker Highlights fluid and inflammation	Identifying fluid collections, edema, inflammatory changes Characterizing cystic lesions or pleural effusions

3. Contrast Agents and Safety Considerations

   • Gadolinium-Based Contrast Materials: Used to enhance vascularity and tissue perfusion in MRI.
   • Advantages of MRI include the absence of ionizing radiation and avoidance of iodinated contrast, reducing certain risks associated with CT. However, gadolinium agents can be contraindicated in patients with severe renal dysfunction due to the risk of nephrogenic systemic fibrosis.

4. Indications and Contraindications for Chest MRI

   Indications	Contraindications / Cautions
   Cardiac imaging: functional assessment of the heart in systole and diastole Vascular and mediastinal tumors: delineation of vascular invasion and soft tissue detail Assessment of complex chest wall or spinal involvement (e.g., Pancoast tumors) Further characterization of indeterminate soft tissue lesions	Presence of certain metallic implants, pacemakers, or devices incompatible with strong magnetic fields Claustrophobia or inability to remain still (though sedation or open MRI scanners may mitigate these issues) Renal insufficiency when using gadolinium-based agents

Ultrasound (US) of the Chest

1. Role of Ultrasound

   Ultrasound is less commonly employed for routine lung imaging because air-filled lung parenchyma impedes sound wave transmission. However, it is highly valuable for pleural assessments and other specific thoracic applications.

2. Evaluating Pleural Effusions and Empyema

   • Ultrasound can differentiate transudates vs. exudates by comparing echogenicity relative to the liver or spleen.
   • Transudates often appear anechoic or hypoechoic (similar or slightly darker than liver).
   • Exudates or empyemas may show internal echoes, septations, or debris, indicating higher protein or cellular content.
   • Real-time guidance for thoracentesis or drainage makes ultrasound indispensable in managing pleural fluid collections.

3. Advantages and Limitations

   • Advantages: No radiation, real-time imaging, portability (e.g., bedside use), excellent for fluid assessment and guided interventions.
   • Limitations: Air in the lungs and bony structures limit visualization of deeper thoracic structures.

Best Imaging Modality for Specific Clinical Scenarios

1. Pleural Effusion

   Ultrasound is highly sensitive for detecting and characterizing pleural fluid, guiding thoracentesis, and differentiating between transudates and exudates.

2. Tumor Invading the Mediastinum

   MRI is often preferred for superior soft tissue delineation and assessment of tumor invasion into mediastinal structures, major vessels, or the spine.

3. Assessment of Heart in Systole and Diastole

   MRI offers detailed cine sequences to visualize cardiac function dynamically.

   CT can provide gated images of the heart but typically relies on rapid data acquisition rather than continuous real-time evaluation.

Written on January 7, 2025

Chatper 3: The Normal Chest X-ray: Reading Like the Pros

Differentiating Alveolar and Interstitial Changes

Understanding the distinction between alveolar (often referred to as radiolucent under normal conditions but appearing radiodense when filled with fluid or exudate) and interstitial (commonly described as radiodense when thickened) lung changes is essential in interpreting chest imaging findings and guiding clinical management. Alveolar and interstitial patterns manifest differently on radiographs or computed tomography (CT) scans and are associated with distinct pathological processes, most notably alveolar pneumonia vs. interstitial pneumonia or alveolar consolidation vs. interstitial thickening.

I. Alveolar Region and Alveolar (Airspace) Changes

1. Normal Appearance of Alveoli
   • The alveoli are typically air-filled, creating a radiolucent appearance on standard chest radiographs.
   • Under normal conditions, the alveolar walls and spaces are not individually visible because of their thin structure and the dominance of air.
2. Alveolar (Airspace) Opacification
   • When alveoli become filled with fluid, pus, blood, or cells (e.g., in pneumonia, hemorrhage, or edema), they appear more radiodense (opaque) on imaging.
   • Alveolar opacification often presents as fluffy, confluent, or homogeneous densities that may obscure normal anatomic landmarks, such as vascular markings or airway outlines.
3. Alveolar Pneumonia (Consolidation)
   • Pathophysiology: Characterized by an infectious or inflammatory process within the alveolar spaces. Exudate accumulates in the alveoli, reducing air content and increasing radiodensity on imaging.
   • Radiological Features:
     • Homogeneous or segmental consolidations.
     • Air bronchograms (air-filled bronchi made visible by surrounding alveolar opacification).
   • Clinical Correlation: Often presents with acute symptoms (fever, productive cough, and localized auscultatory findings).
4. Alveolar Consolidation
   • Definition: Consolidation refers to the filling of alveolar spaces with fluid or cells, leading to increased density.
   • Imaging Appearance:
     • Lobar or segmental distribution of opacities.
     • Tendency to have clearly demarcated borders correlating with anatomical lung segments.

II. Interstitial Region and Interstitial (Supporting Framework) Changes

1. Normal Interstitium
   • The interstitium consists of alveolar septa, connective tissue, and the supporting framework of the lung.
   • Under normal conditions, it contributes subtle linear markings without forming dense, reticular, or nodular patterns on standard chest radiographs.
2. Interstitial Thickening (Radiodense)
   • Thickening or infiltration of the interstitial tissues (by fluid, fibrosis, or inflammatory cells) increases radiodensity in a linear, reticular, or reticulonodular pattern.
   • Unlike alveolar consolidation, the airspace is generally preserved, so air bronchograms are less common.
3. Interstitial Pneumonia
   • Pathophysiology: Involves inflammation primarily within the interstitial and alveolar wall regions rather than the alveolar spaces.
   • Radiological Features:
     • Reticular or reticulonodular markings.
     • Ground-glass opacities on CT scans.
     • More diffuse involvement, often bilateral, reflecting widespread interstitial inflammation.
   • Clinical Correlation: Symptoms may be more chronic or subacute (e.g., progressive dyspnea, a dry cough, and diffuse auscultatory findings).
4. Interstitial Thickening
   • Definition: Thickening of alveolar septa or interstitial tissues by edema, fibrotic changes, or infiltration.
   • Imaging Appearance:
     • Linear septal lines (Kerley B lines).
     • Ground-glass changes on high-resolution CT.
     • “Honeycombing” in fibrotic conditions.

III. Clinical and Diagnostic Implications

1. Alveolar Pneumonia vs. Interstitial Pneumonia
   • Alveolar pneumonia: Typically caused by bacteria (e.g., Streptococcus pneumoniae) presenting with lobar consolidation and acute symptoms.
   • Interstitial pneumonia: More commonly associated with viruses, atypical bacteria, or chronic processes (e.g., Mycoplasma, fungi, or idiopathic pulmonary fibrosis), presenting with a more gradual onset.
2. Alveolar Consolidation vs. Interstitial Thickening
   • Alveolar consolidation: Rapidly developing opacities that can obscure vascular markings, often associated with exudative processes.
   • Interstitial thickening: Progressive radiodensities in linear or reticular patterns suggesting fibrosis or infiltrative disease.
3. Treatment Considerations
   • Alveolar (Consolidation) Processes: Require treatments targeting the cause (e.g., antibiotics for bacterial pneumonia, diuretics for edema).
   • Interstitial Processes: Often managed with anti-inflammatory agents (corticosteroids), immunosuppressants, or supportive measures, depending on the underlying etiology.
4. Prognostic Differences
   • Alveolar disorders can often resolve completely if treated appropriately.
   • Interstitial disorders (particularly fibrotic changes) may result in permanent structural lung alterations if not addressed early.

Written on January 7, 2025

Chatper 4: Chest CT

Major Oblique and Minor Horizontal Fissures (Chapter 5: p73~75)

The human lungs are divided into distinct lobes by anatomical grooves known as fissures. These fissures, namely the major oblique fissure and the minor horizontal fissure, serve as critical landmarks that separate the lobes of the lungs. Their orientation, separation roles, and visibility from various anatomical views are essential for a thorough understanding of pulmonary anatomy and its clinical implications.

Major Oblique Fissure

1. Orientation and Separation Role

   The major oblique fissure is a prominent structure present in both the left and right lungs.

   • In the left lung, this fissure separates the upper lobe from the lower lobe.
   • In the right lung, the major oblique fissure divides the lung into the upper lobe (which includes the middle lobe anteriorly) and the lower lobe, effectively separating the superior and middle portions from the inferior portion.

2. Visibility

   Due to its diagonal orientation, the major oblique fissure is not typically visible from a frontal view.

   It becomes most apparent on a lateral view, where the oblique trajectory through the lung can be observed as a line extending from the apex towards the posterior-inferior border.

Minor Horizontal Fissure

1. Orientation and Separation Role

   The minor horizontal fissure is primarily associated with the right lung and separates the right middle lobe from the right upper lobe.

   • Typically, this fissure runs along or near the level of the fourth rib, extending from the lateral aspect of the lung toward the right major oblique fissure.
   • In an erect patient, the minor fissure is usually horizontal and parallel to the floor, which often allows for its visualization on imaging.
   • Note: Although textbooks commonly refer to the minor fissure in the right lung only, a small percentage of people have a left minor fissure between the lingula and the rest of the upper lobe. Watch for it!

2. Visibility

   In an erect patient, the minor horizontal fissure is often visible in both frontal and lateral views. However, in many patients, the fissure is not perfectly horizontal; its anterior portion or the entire fissure may slope downward or appear bowed, making it visible only on the lateral projection.

   In other individuals, the fissure may be anatomically incomplete and therefore not visible in one or both views. These variations in orientation and completeness account for the frequent inconsistencies in recognizing the minor fissure on standard radiographic images.

Written on January 7, 2025

Radiographic Differentiation of Interstitial and Alveolar Lung Diseases (Chapter 9) (Written January 8, 2025)

Lung parenchyma is broadly divided into two key components: the interstitium (supporting structures such as arteries, veins, and bronchi) and the alveoli (air sacs). On a normal chest radiograph (CXR), these structures manifest distinct appearances that help differentiate various pulmonary pathologies—primarily interstitial lung disease versus alveolar (airspace) filling disease.

Normal Lung Anatomy and Radiographic Appearance

Interstitium

• Composed of the supporting vasculature (arteries and veins), bronchi, and connective tissue.
• On a normal CXR, the branching pulmonary vessels appear prominent near the hilum but diminish in caliber peripherally, eventually disappearing beyond the resolution of the X-ray beam.

Alveoli

• Tiny air-filled sacs where gas exchange occurs.
• Individually too small to visualize on CXR; collectively render the lung fields radiolucent (dark) under normal aeration.

Normal Radiographic Signs

• The interstitial markings gradually fade outward.
• The alveoli are uniformly aerated, imparting a clear, lucent appearance.
• The diaphragms are typically seen at the 9th to 10th posterior rib level on full inspiration.

1. Interstitial Lung Disease

   Thickening or alteration of the supporting structures (bronchi, vessels, connective tissue) while alveoli typically remain aerated. Lungs appear aerated, yet pulmonary markings are increased in number, prominence, or distortion.

   1. Acute vs. Chronic Interstitial Disease

      • Acute Interstitial Changes:
        • Markings appear hazy or ill-defined.
        • No significant angular or irregular distortions of vessels.
      • Chronic Interstitial Changes:
        • Markings are sharp, well-defined, and distorted (e.g., angular, bowed, or irregular).
        • May exhibit characteristic findings such as honeycombing or other fibrotic patterns.

   2. Types of Interstitial Patterns

      1. Reticular (Linear) Pattern
         • Appears as a network of fine lines.
         • May progress to coarse reticulation or honeycombing in chronic stages.
      2. Nodular Pattern
         • Manifests as discrete nodular densities scattered throughout the lungs.
         • Can be focal, multifocal, or diffuse.
      3. Reticulonodular Pattern
         • Combination of both linear and nodular changes.

   3. Silhouette and Air Bronchogram in Interstitial Disease

      • Silhouette Sign: Typically absent because aerated alveoli remain interposed between pulmonary vessels and adjacent structures (e.g., diaphragm, heart, aorta).
      • Air Bronchogram: Rarely seen, since the bronchi are still surrounded by aerated lung tissue.

2. Alveolar (Airspace) Filling Disease

   Filling of alveoli by fluid, exudate, or other material, replacing the normal air content. Portions of the lung appear opaque, obscuring the underlying vascular markings in those areas.

   1. Radiographic Characteristics

      1. Reduced Visibility of Vessels in the consolidated regions.
      2. Homogeneous or Patchy Opacification indicating alveolar filling.
      3. Air Bronchogram Sign
         • Often present because bronchi remain air-filled while the surrounding alveoli are opacified with fluid/disease.
         • Absent if the bronchi themselves are also filled with fluid.
      4. Silhouette Sign
         • Present when consolidated (water-density) alveoli are in direct contact with adjacent water-density structures (e.g., heart border, diaphragm, aorta).
         • Absent if the consolidation does not physically contact a structure of similar density.

   2. Multifocal Alveolar Disease

      Small, multiple areas of alveolar consolidation may not consistently demonstrate air bronchograms (especially if bronchi are filled or if the area of consolidation is too small). The silhouette sign appears only when consolidation abuts a known anatomical border.

Key Radiographic Signs

1. Silhouette Sign
   • Loss of the normal interface between the lung and adjacent structures when both become the same radiographic density.
   • Typical of alveolar consolidation abutting the heart border, diaphragm, or aortic knob.
   • Rare in interstitial disease because some aerated lung typically remains at the interface.
2. Air Bronchogram
   • Visualization of air-filled bronchi within an opaque (consolidated) lung field.
   • Characteristic of alveolar filling disease when bronchi remain patent.
   • Uncommon in interstitial disease because surrounding alveolar spaces are still air-filled.
3. Hyperinflation
   • Diaphragms appear flattened and depressed to or below the 10th posterior rib.
   • Often noted in emphysema, sometimes accompanied by visible bullae (lucent areas devoid of normal lung markings).

Additional Considerations

• Assessing Chronicity: Comparison with prior radiographs is often the most reliable indicator of disease progression or chronicity.
• Honeycombing: Sign of advanced fibrotic change in chronic interstitial processes.
• Distortion of Markings: Another hallmark of chronic interstitial disease.
• Multifocal Alveolar Infiltrates: May not produce a classic air bronchogram if bronchi are obstructed or if the affected areas are too small or widely scattered.

Written on January 8, 2025

Reference

Goodman, L. R. (2006). Felson's principles of chest roentgenology: A programmed text (3rd ed.). Saunders.